<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="dom15920" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39291355</article-id><article-id pub-id-type="pmc">PMC11864493</article-id>
<article-id pub-id-type="doi">10.1111/dom.15920</article-id><article-id pub-id-type="publisher-id">DOM15920</article-id><article-categories><subj-group subj-group-type="overline"><subject>Special Issue Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Special Issue Article</subject></subj-group></article-categories><title-group><article-title>Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes</article-title><alt-title alt-title-type="left-running-head">Anandhakrishnan and Hussain</alt-title></title-group><contrib-group><contrib id="dom15920-cr-0001" contrib-type="author"><name><surname>Anandhakrishnan</surname><given-names>Ananthi</given-names></name><degrees>MRCP</degrees><xref rid="dom15920-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dom15920-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="dom15920-cr-0002" contrib-type="author" corresp="yes"><name><surname>Hussain</surname><given-names>Sufyan</given-names></name><degrees>MRCP</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6611-8245</contrib-id><xref rid="dom15920-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="dom15920-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="dom15920-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>sufyan.hussain@kcl.ac.uk</email></address></contrib></contrib-group><aff id="dom15920-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Diabetes, School of Cardiovascular, Metabolic Medicine and Sciences</named-content>
<institution>King's College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="dom15920-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Diabetes and Endocrinology</named-content>
<institution>Guy's &#x00026; St Thomas' NHS Foundation Trust</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="dom15920-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Institute of Diabetes, Endocrinology and Obesity</named-content>
<institution>King's Health Partners</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Sufyan Hussain, MRCP, Department of Diabetes, Guy's &#x00026; St Thomas' NHS Foundation Trust, King's College London, London, SE1 1UL, UK.<break/>
Email: <email>sufyan.hussain@kcl.ac.uk</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><volume>26</volume><issue>Suppl 7</issue><issue-id pub-id-type="doi">10.1111/dom.v26.S7</issue-id><fpage>27</fpage><lpage>46</lpage><history>
<date date-type="rev-recd"><day>08</day><month>8</month><year>2024</year></date>
<date date-type="received"><day>06</day><month>7</month><year>2024</year></date>
<date date-type="accepted"><day>12</day><month>8</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2024 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DOM-26-27.pdf"/><abstract><title>Abstract</title><p>The development of automated insulin delivery (AID) systems, which connect continuous glucose monitoring (CGM) systems with algorithmic insulin delivery from an insulin pump (continuous subcutaneous insulin infusion, [CSII]), has led to improved glycaemia and quality of life benefits in those with insulin&#x02010;treated diabetes. This review summarizes the benefits gained by the connectivity between insulin pumps and CGM devices. It details the technical requirements and advances that have enabled this, and highlights the clinical and user benefits of such systems. Clinical trials and real&#x02010;world outcomes from the use of AID systems in people with type 1 diabetes (T1D)&#x000a0;will be the focus of this article; outcomes in people with type 2 diabetes (T2D) and other diabetes subtypes will also be discussed. We also detail the limitations of current technological approaches for connectivity between insulin pumps and CGM devices. While recognizing the barriers, we discuss opportunities for the future.</p></abstract><abstract abstract-type="short"><p>Answer questions and earn <ext-link xlink:href="https://health.learning.wiley.com/courses/dom-15920/" ext-link-type="uri">CME</ext-link> credit</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom15920-kwd-0001">continuous glucose monitoring</kwd><kwd id="dom15920-kwd-0002">CSII</kwd><kwd id="dom15920-kwd-0003">insulin pump therapy</kwd><kwd id="dom15920-kwd-0004">type 1 diabetes</kwd><kwd id="dom15920-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Medical Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/W030004/1</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="20"/><word-count count="13700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom15920-cit-9001">
<string-name>
<surname>Anandhakrishnan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>S</given-names>
</string-name>. <article-title>Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes</article-title>. <source>Diabetes Obes Metab</source>. <year>2024</year>;<volume>26</volume>(Suppl. 7):<fpage>27</fpage>&#x02010;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dom.15920</pub-id>
<pub-id pub-id-type="pmid">39291355</pub-id>
</mixed-citation>
</p><fn-group id="dom15920-ntgp-2302"><fn id="dom15920-note-0031"><p>Answer questions and earn <ext-link xlink:href="https://health.learning.wiley.com/courses/dom-15920/" ext-link-type="uri">CME</ext-link> credit</p></fn></fn-group></notes></front><body id="dom15920-body-0001"><sec id="dom15920-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Despite advances in the management of type 1 diabetes (T1D), the daily decision&#x02010;making burden in the pursuit of optimizing glycaemia is significant. Therefore, it is not surprising, that for many living with T1D, glycaemia remains above the recommended targets. In the United States, data from the 2018 Diabetes Exchange registry reports that only 17% of children and 21% of adults with T1D achieve their target HbA1c levels<xref rid="dom15920-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> and, in the UK, 2021&#x02010;2022 National Diabetes Audit data highlights that almost two&#x02010;thirds of adults with T1D do not meet conservative treatment targets for their condition.<xref rid="dom15920-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Establishing connectivity between continuous glucose monitoring (CGM) devices and insulin pumps (continuous subcutaneous insulin infusion [CSII]), leading to the development of closed&#x02010;loop &#x02018;artificial pancreas&#x02019; systems, has transformed the management of, and living with, T1D. It is now extending its reach to those with type 2 diabetes (T2D) and other forms of diabetes. Advances in technology will offer further opportunities for connectivity, but they will also present some challenges. There are risks of already evident widening disparities in access.</p><p>The aim of the current article is to provide a narrative review that reports on how the connectivity between CGM devices and insulin pumps have benefitted people with diabetes. The historical perspective provided sets the scene for the development of connectivity for automated insulin delivery (AID) systems that may be less known or understood by healthcare professionals (HCPs). It also actively addresses current limitations. Overcoming some of the challenges will maximize opportunities to ensure that these systems offer benefits to the widest number of individuals. We provide an overview of outcomes from T1D trials to highlight how outcomes have been improved, with a further focus on diabetes subtypes other than T1D.</p></sec><sec sec-type="background" id="dom15920-sec-0002"><label>2</label><title>BACKGROUND</title><sec id="dom15920-sec-0003"><label>2.1</label><title>Initial insulin pumps and closed&#x02010;loop insulin delivery</title><p>In 1964, Arnold Kadish used an &#x02018;on&#x02013;off&#x02019; control system to connect continuous real&#x02010;time intravenous glucose measurements to two intravenous syringe pumps containing insulin and either glucose or glucagon to maintain glycaemia within a set target range.<xref rid="dom15920-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Although Kadish's system did not utilize algorithmic titration of insulin or glucagon delivery, it is widely credited as the first automated, or &#x02018;closed&#x02010;loop&#x02019;, insulin delivery system. Ten years later, two groups in parallel established communications between intravenous glucose measurements and algorithmic insulin delivery: Albisser's group in Canada<xref rid="dom15920-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="dom15920-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and Pfeffier's group<xref rid="dom15920-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> in Germany developed systems where an algorithm hosted on a microcomputer titrated intravenous insulin and/or glucose delivery depending on intravenous blood glucose levels. Pfeffier's group's system was commercialized as the Biostator<xref rid="dom15920-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> in 1977, although its size and complexity meant that its use was largely confined to research.</p><p>Work in Paris in 1974 by Slama et al.<xref rid="dom15920-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> explored wearable continuous insulin delivery. Insulin was delivered &#x02018;open&#x02010;loop&#x02019; at predetermined basal rates and 15&#x02010;fold higher prandial rates and infused via an intravenous insulin pump worn in a shoulder bag by seven participants with T1D over a trial period of 1&#x02010;5&#x02009;days. Compared with three times per day subcutaneous insulin, the results reported positive glycaemic outcomes. The first portable AID or &#x02018;closed&#x02010;loop&#x02019; system was developed by Shichiri and colleagues in Japan in 1984 using two intravenous pumps for insulin and glucagon, and a subcutaneous glucose sensor connected by a microcomputer&#x02010;hosted algorithm.<xref rid="dom15920-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Trialled in three people with T1D (pwT1D) and seven without diabetes, the system showed superiority compared with multiple daily injections (MDI) or &#x02018;open&#x02010;loop&#x02019; insulin delivery. The practicalities and safety of intravenous insulin delivery limited the wider utilization of such technologies. To address such limitations, Keen, Pickup and colleagues from Guy's Hospital London began work on continuous subcutaneous insulin (insulin pump/CSII) delivery. The outcome of their research showing the feasibility of CSII in 12 participants with insulin&#x02010;dependent diabetes was published in 1978.<xref rid="dom15920-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Following&#x000a0;publication, during the next 4&#x02009;years, several groups reported the safety of CSII use in pwT1D in inpatient<xref rid="dom15920-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="dom15920-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and short&#x02010;<xref rid="dom15920-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="dom15920-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> and long&#x02010;term<xref rid="dom15920-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="dom15920-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="dom15920-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> outpatient settings. This led to the development and commercialization of the first body&#x02010;worn insulin pump in 1983.<xref rid="dom15920-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="dom15920-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>The earliest commercial insulin pumps were large devices infusing insulin via metal needles with a comparatively short battery life, little flexibility in the rate of insulin delivery<xref rid="dom15920-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> and limited safety alarms. Hence, the complications of hyperglycaemia and diabetic ketoacidosis were not uncommon.<xref rid="dom15920-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="dom15920-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="dom15920-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="dom15920-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The 1990s and 2000s saw a revolution in the development of insulin pumps. Safety features such as alerts for infusion set occlusion and low battery or low insulin reservoir were integrated alongside the miniaturization of pump devices, longer&#x02010;life batteries and plastic catheter infusion sets.<xref rid="dom15920-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p></sec><sec id="dom15920-sec-0004"><label>2.2</label><title>CGM development</title><p>With advances in pump device technology, the next limiting step for wider practical development and adoption of closed&#x02010;loop systems became refinements in real&#x02010;time interstitial fluid glucose sensing via CGM devices. The first commercially available CGM device was developed by Minimed (now Medtronic) in 1999 and consisted of a cable physically connecting the sensor and its receiver. While it enabled the recording of glucose values over 3&#x02009;days, data were not available in real time for the user. Manual download onto a computer via a &#x02018;communications cradle&#x02019; was performed by a healthcare provider for retrospective analysis.<xref rid="dom15920-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> This lack of real&#x02010;time connectivity presented another obstacle to the consideration of a practical AID device.</p><p>In 2004, Medtronic's Guardian REAL&#x02010;Time CGM device allowed real&#x02010;time programmable high&#x02010; and low&#x02010;glucose alerts, features that have subsequently become industry standard. In the same year, Dexcom launched the short&#x02010;term sensor, its first CGM device allowing real&#x02010;time glucose review; this was followed, in 2008, by Abbott's real&#x02010;time CGM device, the freestyle navigator.<xref rid="dom15920-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> These first&#x02010;generation CGM devices all necessitated a battery&#x02010;operated secondary receiver for data review.<xref rid="dom15920-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="dom15920-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="dom15920-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Medtronic's Guardian REAL&#x02010;Time also introduced wireless radiofrequency (RF) connectivity between sensor and receiver, and the subsequent development of data transmitter accessories such as the Dexcom SHARE enabled viewing CGM data on handheld devices via wireless upload of receiver data onto the cloud.<xref rid="dom15920-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="dom15920-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> The need for a distinct CGM receiver was removed after Dexcom released the G5, which enabled direct connectivity between the&#x000a0;CGM device and smartphone application.<xref rid="dom15920-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Smartphone connectivity, with options for handheld readers, is now becoming the norm for currently available CGM devices. The majority of CGM options are real time, where interstitial glucose levels are continuously transmitted to a receiver via RF or Bluetooth. The alternative option is intermittently scanned CGM (isCGM). With isCGM, users scan the sensor to obtain readings via near&#x02010;field communication (NFC). The continuous wireless data transfer of realtime CGM (rtCGM) devices facilitates their use in AID systems whilst the requirement for manual scanning in the commercial use of isCGM devices means their adoption&#x000a0;within AID systems is impractical. However, the potential to co&#x02010;opt wireless NFC to enable automated intermittent glucose measurements from isCGM devices may allow the integration of these devices within AID systems.</p></sec><sec id="dom15920-sec-0005"><label>2.3</label><title>The call for connectivity</title><p>The development of smaller, smarter CGM devices and insulin pumps in the 2000s<xref rid="dom15920-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> saw the focus shift towards establishing connectivity between systems. In 2006, the Juvenile Diabetes Research Foundation (JDRF) established the Artificial Pancreas Project targeted towards the development of AID systems.<xref rid="dom15920-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> In 2009, a roadmap to achieving the artificial pancreas comprising six stages of automation was proposed<xref rid="dom15920-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>: stages one to three described systems targeting hypoglycaemia; stage four consisted of hybrid closed&#x02010;loop (HCL) and stage five fully closed&#x02010;loop (FCL) systems; with stage six being a fully automated multihormonal closed&#x02010;loop system.</p><p>The earliest phase of modern connectivity saw the development of low&#x02010;glucose suspend (LGS) devices that suspend insulin delivery when glucose levels fall under a set threshold,<xref rid="dom15920-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> commercialized in 2009 (CE Mark approval of the MiniMed Veo System<xref rid="dom15920-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>). The evolution of LGS systems saw the development of predictive LGS (PLGS) systems that halt insulin delivery in preparedness for hypoglycaemia, and have been in use since early 2015 (MiniMed 640G CE mark January 2015).<xref rid="dom15920-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="dom15920-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="dom15920-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> This was followed by the&#x000a0;development of HCL systems. HCL systems connect rt&#x02010;CGM devices with algorithmic insulin delivery from an insulin pump. The algorithm constantly alters insulin delivery via the pump based on regular CGM&#x02010;derived glucose readings taking into consideration other factors such as current glycaemia, predicted glycaemia and insulin on&#x02010;board. The first HCL systems required manual connectivity between the sensor, algorithm and pump; manual input of sensor glucose values into a computer&#x02010;based algorithm with subsequent manual adjustment of basal insulin infusion rate according to algorithmic calculation necessitated.<xref rid="dom15920-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The adoption of wireless communication between sensor, algorithm and pump has facilitated wider use of HCL systems, with glycaemic and quality of life (QoL) benefits reported both from clinical trials and real&#x02010;world evidence (RWE). Nevertheless, there are still challenges concerning connectivity that need to be overcome.</p></sec></sec><sec id="dom15920-sec-0006"><label>3</label><title>TECHNICAL ADVANCES ENABLING CONNECTIVITY BETWEEN DIABETES DEVICES</title><p>Connectivity between the three limbs of an AID system is key in enabling optimal glycaemic control. The development of the first HCL systems began in tandem with LGS technology.<xref rid="dom15920-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> However, delays to commercialization saw the birth of the open&#x02010;source (OS) closed&#x02010;loop movement.<xref rid="dom15920-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Alongside the #WeAreNotWaiting, in 2013, a group of pwT1D and their families collaborated to develop OS closed&#x02010;loop algorithms to respond to the unmet need for commercial HCL systems. The first OS HCL systems used a hardware radio &#x02018;bridge&#x02019; to communicate between the pump and algorithm because of the built&#x02010;in RF communication of older insulin pumps.<xref rid="dom15920-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> The first OS AID systems implemented LGS technology and subsequent versions were further developed into&#x000a0;HCL systems. In 2016, Medtronic's MiniMed 670G became the first commercially available HCL system<xref rid="dom15920-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> utilizing RF to communicate between a rt&#x02010;CGM sensor and closed&#x02010;loop algorithm housed within the insulin pump. The later adoption of Bluetooth technology within commercial insulin pumps facilitated the housing of commercial and OS closed&#x02010;loop algorithms within secondary handheld mobile devices. Table&#x000a0;<xref rid="dom15920-tbl-0001" ref-type="table">1</xref> provides details of the currently available commercial and OS HCL systems with their connectivity considerations.<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="dom15920-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</p><table-wrap position="float" id="dom15920-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Commercial and open&#x02010;source AID systems.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">System</th><th align="left" valign="bottom" rowspan="1" colspan="1">Algorithm name</th><th align="left" valign="bottom" rowspan="1" colspan="1">Algorithm type</th><th align="left" valign="bottom" rowspan="1" colspan="1">User interface</th><th align="left" valign="bottom" rowspan="1" colspan="1">Compatible CGM device</th><th align="left" valign="bottom" rowspan="1" colspan="1">Compatible insulin pump</th><th align="left" valign="bottom" rowspan="1" colspan="1">Connectivity</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" valign="top" rowspan="1">Open source</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Open APS</td><td align="left" valign="top" rowspan="1" colspan="1">Oref0<xref rid="dom15920-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Insulin dosing based on a number of scenarios that it forecasts with different types of predictions<xref rid="dom15920-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Android and Apple smartphones</p>
<p>Any smartwatch</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G4, G5, G6; Medtronic Real&#x02010;Time Revel and Enlite; other systems via Nightscout<xref rid="dom15920-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Medtronic 512/712, 515/715, 522/722, 523/723, 554/754</td><td align="left" valign="top" rowspan="1" colspan="1">Radiofrequency 900&#x02009;mHZ</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AndroidAPS</td><td align="left" valign="top" rowspan="1" colspan="1">Uses Open APS algorithm with modifications</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>Android smartphone</p>
<p>&#x02018;Wear OS&#x02019; Google smartwatch</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G4, G5, G6; FreeStyle Libre, Libre 2; Eversense; Medtronic Guardian 2; Medtrum A6; PocTech; Gluco24</td><td align="left" valign="top" rowspan="1" colspan="1">AccuChek Spirit Combo; AccuChek Insight; Dana R or RS; Medtronic 512/712, 515/715, 522/722, 523/723554/754 OmniPod Eros</td><td align="left" valign="top" rowspan="1" colspan="1">Radiobridge; Classic Bluetooth; BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Loop</td><td align="left" valign="top" rowspan="1" colspan="1">Loop</td><td align="left" valign="top" rowspan="1" colspan="1">MPC</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Apple smartphone</p>
<p>Apple smartwatch</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G4, (with Dexcom SHARE) G5, G6, G7; Medtronic Enlite 2; FreeStyle Libre with third party software, Freestyle Libre 2</td><td align="left" valign="top" rowspan="1" colspan="1">OmniPod Eros; Medtronic 515/715, 522/722, 523/723, 554/754</td><td align="left" valign="top" rowspan="1" colspan="1">Radiofrequency 916&#x02009;MHz; BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">iAPS<xref rid="dom15920-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Uses Open APS algorithm with modifications</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>Apple smartphone</p>
<p>Apple smartwatch</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Dexcom G5/G6/ONE/G7</p>
<p>Glucose Simulator</p>
<p>Libre Transmitter</p>
<p>Glucose Direct</p>
<p>Medtronic Enlite</p>
<p>Other systems via x&#x02010;drip<xref rid="dom15920-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref> and Nightscout<xref rid="dom15920-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Omnipod DASH pumps</p>
<p>Omnipod Eros pumps</p>
<p>Medtronic 515/715, 522/722, 523/723, Medtronic Worldwide Veo 554/754, Medtronic Canada/Austraian Veo 554/754</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>RileyLink or similar needed for Omnipod Eros</p>
<p>Bluetooth for Omnipod DASH</p>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Trio<xref rid="dom15920-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Uses Open APS algorithm with modifications</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>Apple Smartphones</p>
<p>Apple Smartwarch</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Dexcom G5/G6/ONE/G7</p>
<p>Glucose Simulator</p>
<p>Libre Transmitter</p>
<p>Glucose Direct</p>
<p>Medtronic Enlite</p>
<p>Other systems via x&#x02010;drip<xref rid="dom15920-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref> and Nightscout<xref rid="dom15920-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Omnipod DASH pumps</p>
<p>Omnipod Eros pumps</p>
<p>Medtronic 515/715, 522/722, 523/723, Medtronic Worldwide Veo 554/754, Medtronic Canada/Austraian Veo 554/754</p>
<p>DanaRS (in the future)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>RileyLink or similar for Omnipod Eros</p>
<p>Bluetooth for Omnipod DASH</p>
</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Commercial</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medtronic 670G/770G</td><td align="left" valign="top" rowspan="1" colspan="1">SmartGuard</td><td align="left" valign="top" rowspan="1" colspan="1">PID</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Insulin pump</p>
<p>770G: Android or Apple phone (view only)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Guardian Link 3</td><td align="left" valign="top" rowspan="1" colspan="1">Medtronic 670G/770G</td><td align="left" valign="top" rowspan="1" colspan="1">Radiofrequency 2.4&#x02009;GHz</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medtronic 780G</td><td align="left" valign="top" rowspan="1" colspan="1">SmartGuard</td><td align="left" valign="top" rowspan="1" colspan="1">PID and FL</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Insulin pump</p>
<p>Android or Apple phone (view only)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Guardian Link 4</td><td align="left" valign="top" rowspan="1" colspan="1">Medtronic 780G</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Tandem Control&#x02010;IQ</td><td align="left" valign="top" rowspan="1" colspan="1">Control IQ 1.0</td><td align="left" valign="top" rowspan="1" colspan="1">PID</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Insulin pump</p>
<p>Android or Apple phone app (t:connect mobile in the United States for mobile view and bolus)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G6</td><td align="left" valign="top" rowspan="1" colspan="1">Tandem T:Slim x2</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CamAPS Fx</td><td align="left" valign="top" rowspan="1" colspan="1">CamAPS FX</td><td align="left" valign="top" rowspan="1" colspan="1">MPC</td><td align="left" valign="top" rowspan="1" colspan="1">Android phone</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Dexcom G6</p>
<p>Freestyle Libre 3</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">DANA RS; Dana&#x02010;I; Ypsopump</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diabeloop DBLG1</td><td align="left" valign="top" rowspan="1" colspan="1">DBLG1</td><td align="left" valign="top" rowspan="1" colspan="1">MPC</td><td align="left" valign="top" rowspan="1" colspan="1">Separate portable device or Android or Apple phone app</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G6</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Kaleido patch</p>
<p>AccuCheck Insight; Dana&#x02010;I; EOFlow</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Omnipod 5</td><td align="left" valign="top" rowspan="1" colspan="1">SmartAdjust</td><td align="left" valign="top" rowspan="1" colspan="1">MPC</td><td align="left" valign="top" rowspan="1" colspan="1">Controller or app available for certain android smartphones</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Dexcom G6</p>
<p>Freestyle Libre 3</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">Omnipod 5 patch pump</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Medtrum touchcare Nano<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="dom15920-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Artifical Pancreatic Algorithm</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Separate portable device or Android or Apple phone app</td><td align="left" valign="top" rowspan="1" colspan="1">Touchcare Nano CGM</td><td align="left" valign="top" rowspan="1" colspan="1">Medtrum Easy Patch</td><td align="left" valign="top" rowspan="1" colspan="1">BLE</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">I&#x02010;let bionic pancreas system<xref rid="dom15920-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="dom15920-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">MPC</td><td align="left" valign="top" rowspan="1" colspan="1">Android or Apple phone app</td><td align="left" valign="top" rowspan="1" colspan="1">Dexcom G6 or DexcomG7</td><td align="left" valign="top" rowspan="1" colspan="1">iLet insulin pump</td><td align="left" valign="top" rowspan="1" colspan="1">Bluetooth</td></tr></tbody></table><table-wrap-foot id="dom15920-ntgp-0002"><fn id="dom15920-note-0001"><p>
<italic toggle="yes">Note</italic>: Information sourced from Braune et al.<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> unless otherwise detailed.</p></fn><fn id="dom15920-note-0002"><p>Abbreviations: AID, automated insulin delivery; BLE, bluetooth low energy; CGM, continuous glucose monitoring; FL, fuzzy logic; MPC, model predictive control; PID, proportional integrative derivative.</p></fn><fn id="dom15920-note-0003"><label>
<sup>
<bold>a</bold>
</sup>
</label><p>Nightscout is an open&#x02010;source project that allows real time access to a CGM and insulin pump data via cloud upload.</p></fn><fn id="dom15920-note-0004"><label>
<sup>b</sup>
</label><p>x&#x02010;drip is an Android app that collates data from CGM&#x000a0;devices and insulin pumps to be uploaded to Nightscout.</p></fn></table-wrap-foot></table-wrap><p>Communication dropouts between components of HCL systems may result from connectivity being interrupted by physical barriers, interference from another wireless device, or inadvertent disabling of wireless connectivity on the algorithm&#x02010;hosting device. Communication errors may also occur between either the insulin pump or rtCGM device and platforms designed to receive the data upload; these are secondary to issues related to data (internet or cellular), Bluetooth connectivity or incorrect login details on mobile&#x02010;based apps. Battery life, whether in the CGM transmitter, insulin pump or mobile device, could also pose a barrier to connectivity.<xref rid="dom15920-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p><sec id="dom15920-sec-0007"><label>3.1</label><title>Radiofrequency communication</title><p>RF waves are a subgroup of electromagnetic waves that transmit data wirelessly within a broad frequency (typically 3&#x02009;kHz&#x02010;300&#x02009;GHz) and distance range. The lower the frequency, the wider the transmission range, but the lower the rate of data transfer.<xref rid="dom15920-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> RF waves are utilized by electrical devices for communication (between one or more antennae and receivers located on separate devices) and for non&#x02010;communicative purposes. Because of their large communication range, devices operating via RF can consume significant energy, affecting battery life. This substantially impacts battery requirements, as well as the weight and size of devices.</p><p>The industrial, scientific and medical (ISM) radio bands are internationally designated parts of the RF spectrum reserved for use by ISM fields, with the exclusion of telecommunication devices. Although ISM bands vary between countries, certain bands are shared, one of which is 2.4 GHz.<xref rid="dom15920-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="dom15920-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> The 2.4&#x02010;GHz ISM radio band was utilized to enable older generation insulin pumps to deliver remote boluses through a separate handheld device.<xref rid="dom15920-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> This device also functioned as a CGM receiver for the MiniMed 630G with a Contour Next Link 2.4 meter,<xref rid="dom15920-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> or as a standalone remote controller for the MiniMed MMT&#x02010;500 or MMT&#x02010;503 controllers used with Medtronic's MiniMed 508 or MiniMed Paradigm families of insulin pumps.<xref rid="dom15920-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="dom15920-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> However, the RF communications between the MiniMed remote controller systems were found to pose cybersecurity risks with the potential for unauthorized access to, and control of, insulin delivery. This led to an urgent discontinuation and device recall of these systems by Medtronic in 2018.<xref rid="dom15920-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="dom15920-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> It was the utilization of such loopholes to secure wireless RF connectivity that facilitated the development of early versions of OS closed&#x02010;loop systems. In the commercial world, Medtronic initially used the 2.4&#x02010;GHz frequency ISM band for wireless communication in its 640G<xref rid="dom15920-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> and 670G<xref rid="dom15920-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> AID systems, later transitioning to the use of Bluetooth low energy (BLE) in its most advanced HCL system, the MiniMed 780G.<xref rid="dom15920-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</p></sec><sec id="dom15920-sec-0008"><label>3.2</label><title>Bluetooth low energy</title><p>The designation of ISM bands aimed to mitigate interference between wireless communications from ISM and telecommunication devices. However, increasing congestion of the RF spectrum has seen wireless communication systems, including Wi&#x02010;Fi and Bluetooth, making use of the 2.4&#x02010;GHz ISM RF band.</p><p>Bluetooth is a form of wireless technology that operates via 2.4&#x02010;GHz RF waves and connects digital devices over short distances. Today's Bluetooth technology includes classic Bluetooth and BLE.<xref rid="dom15920-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="dom15920-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> BLE is increasingly used in healthcare technology because of its reduced power consumption compared with classic Bluetooth and ISM RF bands. BLE operates via periodic data streaming between communicating devices that become simultaneously active from dormant states.<xref rid="dom15920-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Although this intermittent transfer is not compatible with phone conversations or streaming videos, it provides a low&#x02010;power option for systems that exchange intermittent data such as HCL systems, which cycle their closed&#x02010;loop communication between the rtCGM device, algorithm and insulin pump every 5&#x02010;12&#x02009;minutes, depending on the system.<xref rid="dom15920-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Significant changes in glucose levels are unlikely to occur during the short intervals between periodic data transfers via BLE&#x02010;utilizing HCL systems. This feature, however, could serve as a contingency measure to accommodate for communications not received because of interruptions in connectivity.</p><p>HCL systems communicating via Bluetooth can host algorithms in a device distinct from the insulin pump, although proximity to this secondary device is needed. In those using patch pump systems, this secondary device provides both glycaemic and connectivity alerts (provided by either an insulin pump or a secondary handheld device in tubed systems).</p></sec><sec id="dom15920-sec-0009"><label>3.3</label><title>Interference</title><p>Interference in wireless communication is the process by which communication between a transmitter and its receiver is interrupted or weakened. Interference can be electromagnetic, environmental or can come from other sources (Figure&#x000a0;<xref rid="dom15920-fig-0001" ref-type="fig">1</xref>).<xref rid="dom15920-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="dom15920-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Real&#x02010;world outcomes with the first commercial closed&#x02010;loop system, the Medtronic 670G,<xref rid="dom15920-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> reported that 62% of those discontinuing after 1&#x02009;year cited sensor issues, including unplanned system exits from auto mode, as reasons for closed&#x02010;loop discontinuation. Findings suggest the quality of wireless connectivity between limbs of a closed&#x02010;loop system to be a key factor in determining device usability. Because interference affects the quality of wireless transmission, reducing interference is probable to increase the reliability, thus the usability, of closed&#x02010;loop systems.</p><fig position="float" fig-type="FIGURE" id="dom15920-fig-0001"><label>FIGURE 1</label><caption><p>Interference to wireless connectivity; attenuation of Bluetooth signal strength occurs naturally with distance and is also influenced by interference that can be broadly classed as environmental or electromagnetic. Environmental obstacles between the transmitter and receiver can degrade connectivity and include physical barriers like walls, objects, the human body and changes in transmission media from water to air. Reflective surfaces that scatter radio waves and humidity also cause interference.<xref rid="dom15920-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Electromagnetic interference can be caused by communicative or non&#x02010;communicative devices operating via radiofrequency. Sound waves can cause interference to other sound&#x02010;producing devices and light transmission can interfere with communication systems transmitting signals through other frequencies.<xref rid="dom15920-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>
</p></caption><graphic xlink:href="DOM-26-27-g002" position="anchor" id="jats-graphic-1"/></fig><p>Wireless connectivity requires a clear line of sight between transmitter and receiver. For HCL systems housing interface and algorithms within an insulin pump and receiving communications from a CGM device, a clear line of sight may be maintained, but electromagnetic interference (EMI) can still cause connectivity issues leading to additional frustration and device burden. EMI can occur because of crowding, where the number of wireless signals that share the same frequency cause interference to communications within one or more systems.<xref rid="dom15920-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> Adjacent&#x02010;channel interference is another form of EMI that occurs when devices operating at overlapping frequencies cause interference to communications within one or more systems.<xref rid="dom15920-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Cross&#x02010;technology interference arises when different wireless technologies using the same frequency waves (such as ISM bands, Wi&#x02010;Fi and Bluetooth operating in the 2.4&#x02010;GHz frequency) cause interference to communications within one or more systems.<xref rid="dom15920-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> EMI from devices like microwave ovens (that operate at 2.4&#x02010;GHz frequency), mobile phones and airport security systems<xref rid="dom15920-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> may also occur, the latter being especially relevant to HCL systems, with the extent of interference varying between manufacturers.</p><p>Environmental interference includes weather conditions like rain and humidity that can affect wireless transmission and physical barriers that can weaken signals or distort the line of sight between transmitter and receiver. Such barriers include water, which is known to attenuate wireless signalling, although recent data have shown that the Omnipod 5 (OP5) patch pump, which utilizes BLE, maintains connectivity during submersion in water for interdevice distances of up to 13 cm.<xref rid="dom15920-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> The human body can also act as a source of environmental interference, with human tissue able to absorb radiation at the 2.4GHz frequency.<xref rid="dom15920-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> A recent experiment exploring Bluetooth signal attenuation through human body tissue analogues showed attenuation from muscle tissue to be greater than analogues of water or fat tissue<xref rid="dom15920-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>; with regards to clinical practice, alterations in HCL connectivity may be impacted by user body composition. Absorbability by human tissues may also raise safety concerns regarding the use of Bluetooth on wearable medical devices. However, Bluetooth technology has a power output well within the limits specified by the International Commission on Non&#x02010;Ionizing Radiation Protection, and thus is generally considered to be safe.<xref rid="dom15920-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>
</p><p>Interference to connectivity within HCL systems may have safety implications, and although interference from HCL systems to secondary devices is less of a safety concern, it can cause day&#x02010;to&#x02010;day frustrations, and interference between HCL and other medical electrical equipment is also possible. Strategies for mitigating interference include increasing the distance between, or turning off interfering external devices,<xref rid="dom15920-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="dom15920-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> although the practicality of achieving this may prove challenging at times. Bluetooth technology employs a number of techniques to mitigate EMI (Figure&#x000a0;<xref rid="dom15920-fig-0002" ref-type="fig">2</xref>).<xref rid="dom15920-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> One such technique is known as adaptive frequency hopping (AFH). Bluetooth enables AFH by dividing its frequency band into smaller channels (40 for BLE and 79 for classic Bluetooth), and rapidly hops between these channels during signal transmission. This reduces the likelihood of occupying a given frequency at a given time. To further minimize interference, Bluetooth adjusts its hopping sequence dynamically and monitors and avoids channels that are noisy or busy.<xref rid="dom15920-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="dom15920-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="dom15920-fig-0002"><label>FIGURE 2</label><caption><p>Methods used by Bluetooth technology to maintain connectivity; packets refer to small portions of larger data. Clockwise: adaptive frequency hopping is the process of dynamically switching between communication channels to reduce the likelihood of interference; despite interventions to prevent interference, data loss can still occur; acknowledgements confirm receipt of packages. Automatic re&#x02010;transmission is the process of sending multiple copies of data packets to reduce the likelihood of signal contamination by interference. Smaller, faster packets reduce the likelihood of data being intercepted by interfering signals.<xref rid="dom15920-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>
</p></caption><graphic xlink:href="DOM-26-27-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="dom15920-sec-0010"><label>3.4</label><title>Cybersecurity</title><p>Despite the benefits of wireless connectivity between CGM devices and insulin pumps, the increased utilization of wireless connectivity brings with it added cybersecurity concerns. Devices operating via RF and Bluetooth offer authentication and encryption that act together to create secure connectivity between communicating devices.<xref rid="dom15920-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> However, both are optional features, so mandating their use may assist in preventing unauthorized data access. Devices operating via Bluetooth announce when they are available for pairing. This can be detected by other devices within the proximity. Although device authentication can prevent an individual's personal device pairing with unknown devices, the user could be identified during announcement,&#x000a0;and unauthorized access to data whilst authenticated devices are announcing themselves available for&#x000a0;pairing is not impossible. Switching devices to &#x02018;not discoverable&#x02019; modes may protect against such risks without affecting connectivity between authenticated paired devices. In those HCL systems housing algorithms within smartphone applications (apps), the possibility of security breaches from corrupt mobile downloads or installed apps is also possible.<xref rid="dom15920-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> The use of multifactor authentication to access app data may mitigate this risk.</p><p>The ability of OS systems to incorporation newer insulin pumps utilizing Bluetooth connectivity (Table&#x000a0;<xref rid="dom15920-tbl-0001" ref-type="table">1</xref>) proves that even advancing methods of wireless connectivity are not infallible. Identifying means to mitigate cybersecurity breaches may facilitate user safety and trust within commercial systems.</p></sec><sec id="dom15920-sec-0011"><label>3.5</label><title>Cloud upload</title><p>Many HCL systems now automatically upload data to the cloud. Remote access to data has been shown to be important to pwT1D<xref rid="dom15920-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> and their carers,<xref rid="dom15920-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> with the potential to facilitate personalized clinical consultations<xref rid="dom15920-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> and telemedicine.<xref rid="dom15920-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> In addition, the obviated need for software and hardware for data upload and storage could also provide cost&#x02010; and energy&#x02010;saving benefits. The available data stored on the cloud are also accessible to HCPs and relevant stakeholders, forming a useful resource for audit and research, with the potential to impact outcomes for broad populations. Access to broad datasets may also facilitate the development of artificial intelligence (AI)&#x02010;assisted algorithmic insulin delivery, but careful legislation will be required to ensure consensual responsible use of data. To this end, ensuring the confidentiality of the user, the integrity of uploaded data, and clear establishment of the ownership and privacy of healthcare information are key security considerations when it comes to the storage of cloud&#x02010;based data;<xref rid="dom15920-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> the latter preventing unauthorized access without approval from all relevant stakeholders. It must also be remembered that the ease and efficacy of access to systems operating via cloud&#x02010;based systems depend on the strength and availability of internet connection,<xref rid="dom15920-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> and not all people with diabetes and/or their carers may have access to the technology required. Figure&#x000a0;<xref rid="dom15920-fig-0003" ref-type="fig">3</xref> illustrates the advantages and disadvantages of using the cloud.</p><fig position="float" fig-type="FIGURE" id="dom15920-fig-0003"><label>FIGURE 3</label><caption><p>The pros and cons of automated wireless upload to the &#x02018;cloud&#x02019;; the advantages of cloud upload include automated access to glucose data, removing the need for manual glucose diaries, benefitting those with diabetes by reducing the burden of management and HCPs by allowing access to large volumes of datasets. The cost and energy benefits, ability to facilitate personalized care and telemedicine, and being a broad data source for research and audit, are other advantages of using automated wireless upload to the cloud. Limitations come from the necessity for HCPs to access multiple data platforms to access data from patients using different technologies. Similarly, for people with diabetes when transitioning from continuous glucose monitoring alone, a sensor augmented pump or open&#x02010;loop to hybrid closed&#x02010;loop disconnection from previous data platforms with download of new data platforms and/or smartphone software is needed. The pre&#x02010;existing platform remains active, however, and although data&#x02010;protection processes are in place, these are not immune to security breaches. A lack of interoperability standards and the need for internet connectivity limiting accessibility are other limitations of automated wireless upload of glucose data to the cloud. HCP, healthcare professional.</p></caption><graphic xlink:href="DOM-26-27-g005" position="anchor" id="jats-graphic-5"/></fig></sec></sec><sec id="dom15920-sec-0012"><label>4</label><title>CURRENTLY AVAILABLE SYSTEMS</title><p>Currently available HCL systems are grouped as either commercial or OS systems; both comprise a CGM device, insulin pump and algorithm. While currently available commercial HCL systems are limited to specified pump and sensor combinations, OS systems provide interoperability between a number of commercial insulin pumps and CGM devices and also offer smartwatches as an added user interface<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> (Table&#x000a0;<xref rid="dom15920-tbl-0001" ref-type="table">1</xref>).</p><p>Five OS AID systems are most commonly in use in the OS closed&#x02010;loop community: (i) OpenAPS communicates via RF<xref rid="dom15920-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>; (ii) AndroidAPS uses the OpenAPS algorithm, on an Android smartphone, communicating via radio&#x02010;bridge, RF, Classic Bluetooth or BLE; (iii) Loop, on an Apple iPhone smartphone or smartwatch, communicating via RF or BLE<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>; (iv) iAPS<xref rid="dom15920-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>; and (v) Trio,<xref rid="dom15920-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> both on an Apple iPhone smartphone or smartwatch using Bluetooth connectivity, or via a separate device that converts the RF communications of older insulin pumps to Bluetooth waves (such as RileyLink).<xref rid="dom15920-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="dom15920-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Eight commercially available HCL systems are now approved for use in pwT1D across Europe and North America. Commercial systems host their algorithm within the insulin pump (670G, 780G, Control&#x02010;IQ, i&#x02010;Let<xref rid="dom15920-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="dom15920-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>), on a separate handheld (OP5) or smartphone device (CamAPS&#x02010;FX and Diabeloop, Medtrum Touchcare Nano), and utilize BLE or RF communications.<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="dom15920-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> For those systems compatible with specific smartphone devices, the need to purchase a compatible device may limit accessibility, and operating system software updates also have the potential to cause connectivity issues.</p><sec id="dom15920-sec-0013"><label>4.1</label><title>Algorithm development</title><p>Mathematical models of glucose&#x02013;insulin interactions have been studied during the last 50&#x02009;years<xref rid="dom15920-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> with several trialled in silico and in clinical studies.<xref rid="dom15920-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> Three classes of control algorithm are in use by currently available commercial HCL systems. The studies of Hovorka et al.<xref rid="dom15920-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="dom15920-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> first outlined the model predictive control (MPC) algorithm that titrates insulin delivery based on predicted changes to glycaemia factoring in rtCGM data, insulin administered to date and expected fluctuations in glucose levels, among other variables.<xref rid="dom15920-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>, <xref rid="dom15920-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> The proportional integral derivative (PID) algorithm was first described by Steil et al.,<xref rid="dom15920-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> and it alters insulin delivery by analysing rtCGM glucose measurements against the extent of deviation from target glucose (proportional component), the absolute difference between rtCGM&#x02013;derived glucose and target glucose (integral component), as well as the rate of change of measured glucose (derivative component).<xref rid="dom15920-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref>, <xref rid="dom15920-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> In 2010, the MD&#x02010;Logic algorithm using fuzzy logic models to drive insulin delivery was piloted; instead of using mathematical models, insulin delivery is altered based on predicted decisions that would be made by diabetes clinicians in response to detected rtCGM metrics.<xref rid="dom15920-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> The development of further models, including adaptations and future potential to incorporate AI and machine learning (ML), is ongoing. Algorithm details and development from industry and commercial systems remain proprietary, whereas those of OS systems can be accessed publicly.</p></sec><sec id="dom15920-sec-0014"><label>4.2</label><title>Processor requirements</title><p>Current control algorithms not only receive information from CGM devices and insulin pumps every few minutes, but are adaptive, altering insulin delivery from the experience of their users<xref rid="dom15920-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>, <xref rid="dom15920-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>; however, such complex calculations can pose challenges if the algorithms are hosted on devices with low processing power (e.g. insulin pumps or mobile phones).<xref rid="dom15920-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>
</p></sec></sec><sec id="dom15920-sec-0015"><label>5</label><title>CLINICAL BENEFITS IN T1D</title><p>CGM and insulin pump devices may be used independently or together as sensor&#x02010;augmented insulin pump therapy (SAP). Although CGM and insulin pump devices, improved glycaemic control when compared with MDI<xref rid="dom15920-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>, <xref rid="dom15920-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>, <xref rid="dom15920-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>&#x000a0;and insulin pump<xref rid="dom15920-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> alone, their&#x000a0;use independently,&#x000a0;or in tandem as SAP, does not reduce the management burden of T1D.<xref rid="dom15920-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> When AID systems targeting hypoglycaemia were compared with SAP, LGS devices were shown to improve hypoglycaemia without increases in HbA1c,<xref rid="dom15920-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="dom15920-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> and PLGS were shown to reduce the severity and duration of hypoglycaemia,<xref rid="dom15920-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="dom15920-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> with resultant QoL benefits in pwT1D.<xref rid="dom15920-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> However, increased incidences of hyperglycaemia were reported with PLGS systems in a paediatric population.<xref rid="dom15920-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref>
</p><p>Glycaemic benefits from trials and RWE in pwT1D have been detailed in recent systematic reviews on commercial HCL systems.<xref rid="dom15920-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Several meta&#x02010;analyses of randomized controlled trials (RCTs) report on the comparative efficacy and safety of HCL systems in pwT1D compared with MDI or SAP.<xref rid="dom15920-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>, <xref rid="dom15920-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref>, <xref rid="dom15920-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>, <xref rid="dom15920-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref>, <xref rid="dom15920-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref>, <xref rid="dom15920-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>, <xref rid="dom15920-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref>, <xref rid="dom15920-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref> Baseline clinical characteristics were seen to influence outcomes from HCL, where those with the highest baseline HbA1c and lowest time in range (3.9&#x02010;10&#x02009;mmol/L) were seen to have the greatest glycaemic benefits.<xref rid="dom15920-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref>, <xref rid="dom15920-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref> Further RWE from the UK also highlights benefits in people with higher baseline HbA1c.<xref rid="dom15920-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref> Recent studies have also highlighted benefits during pregnancy.<xref rid="dom15920-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref>, <xref rid="dom15920-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref> Variations in the design of clinical trials impair the ability to perform between&#x02010;study comparisons, and the absence of a comparator in single&#x02010;arm trials limits interpretation of the relative contributions of HCL use and study effect on observed outcomes.</p><p>Outcomes from OS systems have also been extensively collected in real&#x02010;world settings.<xref rid="dom15920-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref>, <xref rid="dom15920-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> RCTs for OS systems have been more difficult because of regulatory and funding constraints. Nevertheless, the CREATE trial provided data for a multicentre, open&#x02010;label RCT for a modified version of AndroidAPS.<xref rid="dom15920-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref>
</p><sec id="dom15920-sec-0016"><label>5.1</label><title>Psychological and quality of life benefits in T1D</title><p>Real&#x02010;world studies and clinical trials of HCL systems in T1D are increasingly including person&#x02010;reported outcome measures (PROMs) evaluating QoL changes as outcome measures. A meta&#x02010;analysis of reported PROMs reported a trend towards improvements in diabetes&#x02010;specific distress and a reduction in hypoglycaemia fear,<xref rid="dom15920-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref> with no change in generic QoL outcomes. While not reported consistently, HCL systems may also have positive effects on subjective and objective sleep in pwT1D,<xref rid="dom15920-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> parents of children with T1D<xref rid="dom15920-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref> and women with T1D using HCL systems in pregnancy. Reductions in the physical, mental and emotional demands of diabetes in pregnancy were also reported in the latter group.<xref rid="dom15920-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref>
</p><p>Qualitative analyses of semistructured interviews further detail the QoL and psychosocial impacts of HCL systems; reductions in the decision&#x02010;making burden, as well as feelings of stigmatization and worry were reported in children, young people and adults with T1D, alongside increased flexibility, spontaneity and confidence.<xref rid="dom15920-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>, <xref rid="dom15920-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref> Interestingly, qualitative work has shown that, as with glycaemic outcomes with HCL systems, baseline characteristics influence outcomes; those with higher baseline HbA1c tend to report greater satisfaction and trust in HCL systems, while those with better baseline control are more probable to engage in compensatory behaviour and experience greater cognitive and emotional stress in the event of suboptimal auto&#x02010;mode performance.<xref rid="dom15920-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref> As with glycaemic outcomes, skewed ethnic and socioeconomic representation limits interpretation. Furthermore, lack of a consensus in measuring and reporting PROMs across studies makes it difficult to draw effective comparisons and conclusions.</p></sec><sec id="dom15920-sec-0017"><label>5.2</label><title>HCL systems in other diabetes subtypes</title><p>The evidence for HCL use in people with type 2 diabetes (pwT2D) is small but expanding (Table&#x000a0;<xref rid="dom15920-tbl-0002" ref-type="table">2</xref>). One small multicentre outpatient study<xref rid="dom15920-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref> and a small single&#x02010;arm study<xref rid="dom15920-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref> in pwT2D using insulin therapy show the feasibility of HCL systems, but their cohort sizes and study periods limit interpretation. RWE and randomized studies with comparator groups are needed to determine the practicality and efficacy of different HCL systems in pwT2D. Limited small, short&#x02010;term studies assessing outcomes of closed&#x02010;loop therapies in those with cystic fibrosis&#x02010;related diabetes have also been undertaken<xref rid="dom15920-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref>, <xref rid="dom15920-bib-0121" ref-type="bibr">
<sup>121</sup>
</xref> (Table&#x000a0;<xref rid="dom15920-tbl-0002" ref-type="table">2</xref>). A larger study is currently being undertaken in the UK.<xref rid="dom15920-bib-0122" ref-type="bibr">
<sup>122</sup>
</xref>
</p><table-wrap position="float" id="dom15920-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Clinical trials of closed&#x02010;loop systems in T2D and CFRD.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="5" align="left" valign="bottom" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">i. Duration</th><th rowspan="5" align="left" valign="bottom" colspan="1">Closed&#x02010;loop intervention</th><th rowspan="5" align="left" valign="bottom" colspan="1">Methods</th><th rowspan="5" align="left" valign="bottom" colspan="1">Primary outcomse</th><th rowspan="2" colspan="5" align="left" valign="bottom">Outcomes measures</th><th rowspan="5" align="left" valign="bottom" colspan="1">Study&#x02010;related adverse events</th><th rowspan="5" align="left" valign="bottom" colspan="1">Limitations</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">ii. Participants</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">iii. Country</th><th rowspan="3" align="left" valign="bottom" colspan="1">% TIR</th><th rowspan="3" align="left" valign="bottom" colspan="1">% Time below range</th><th rowspan="3" align="left" valign="bottom" colspan="1">% Time above range</th><th rowspan="3" align="left" valign="bottom" colspan="1">Other outcomes</th><th rowspan="3" align="left" valign="bottom" colspan="1">Patient&#x02010;related outcome measures</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">iv. Study type</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">v. Key inclusion</th></tr></thead><tbody valign="top"><tr><td colspan="12" align="left" valign="top" rowspan="1">T2D &#x02013; HCL</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Davis et al. (2023)<xref rid="dom15920-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="dom15920-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0001"><list-item id="dom15920-li-0001"><p>2&#x02009;mo</p></list-item><list-item id="dom15920-li-0002"><p>24 adults with T2D</p></list-item><list-item id="dom15920-li-0003"><p>United States</p></list-item><list-item id="dom15920-li-0004"><p>Retrospective analysis</p></list-item><list-item id="dom15920-li-0005"><p>On insulin, no pump use within 3&#x02009;mo of screening</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>HCL</p>
<p>OP5 with SmartAdjust</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Single&#x02010;arm multicentre outpatient study comparing AID to insulin pen</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % Time with sensor glucose &#x02265;&#x02009;250&#x02009;mg/dL and &#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3;70&#x02010;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x02265;&#x02009;250&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>&#x025b3;HbA1c</p>
<p>&#x02212;1.3%&#x02009;&#x000b1;&#x02009;0.7% <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.0001</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Increased insulin delivery satisfaction</td><td rowspan="2" align="left" valign="top" colspan="1">Nil</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Single&#x02010;arm study</p>
<p>Sample size</p>
<p>Study duration</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>+21.9&#x02009;&#x000b1;&#x02009;15.2</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.0001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>No significant change</p>
<p>Pen 0 (IQR 0, 0.06) AID</p>
<p>0 [IQR 0, 0.03]</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.4543</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02212;16.9&#x02009;&#x000b1;&#x02009;16.2</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.0001</p>
</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Levy et al. (2024)<xref rid="dom15920-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0002"><list-item id="dom15920-li-0006"><p>6&#x02009;wk</p></list-item><list-item id="dom15920-li-0007"><p>30 adults with T2D</p></list-item><list-item id="dom15920-li-0008"><p>United States</p></list-item><list-item id="dom15920-li-0009"><p>Prospective single&#x02010;arm trial</p></list-item><list-item id="dom15920-li-0010"><p>On insulin, no previous Tandem T&#x02010;slim use</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>HCL</p>
<p>Tandem T:Slim with Control IQ</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Prospective single&#x02010;arm study</td><td rowspan="2" align="left" valign="top" colspan="1">Not specified</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 70&#x02010;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 250&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Baseline HbA1c influences TIR</p>
<p>changes; greater change in &#x02265;&#x02009;8% baseline HbA1c</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>PROMIS Sleep and DIDS Diabetes Impact score no change</p>
<p>Reduced DIDS Device satisfaction score 6&#x02009;wk from screening <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.006</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Nil</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Single&#x02010;arm study</p>
<p>Sample size</p>
<p>Study duration</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>+15% (95% CI 6%, 24%)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.004</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>No significant change</p>
<p>&#x02212;0.06 (95% CI &#x02212;0.19, &#x02212;0.07)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.32</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02212;4.1 (95% CI &#x02212;7.5%, &#x02212;0.6%)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;&#x02013;.02</p>
</td></tr><tr><td colspan="12" align="left" valign="top" rowspan="1">T2D &#x02013; FCL</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Thabit et al. (2016)<xref rid="dom15920-bib-0123" ref-type="bibr">
<sup>123</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0003"><list-item id="dom15920-li-0011"><p>72&#x02009;h</p></list-item><list-item id="dom15920-li-0012"><p>40 adults with T2D</p></list-item><list-item id="dom15920-li-0013"><p>UK</p></list-item><list-item id="dom15920-li-0014"><p>Randomized control trial</p></list-item><list-item id="dom15920-li-0015"><p>On insulin +/&#x02212; other glucose&#x02010;lowering agents</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>FCL</p>
<p>Dana&#x02010;R with MPC algorithm</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Single&#x02010;centre, open&#x02010;label, parallel&#x02010;group inpatient study comparing FCL to standard insulin therapy</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % Time in target range (5.6&#x02010;10&#x02009;mmol/L [100&#x02010;180&#x02009;mg/dL])</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 5.6&#x02010;10&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;3.5&#x02009;mmolL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 10&#x02009;mmol/L</td><td rowspan="2" align="left" valign="top" colspan="1"/><td rowspan="2" align="left" valign="top" colspan="1">
<p>90% happy to have automated control</p>
<p>95% would recommend to a friend or family member if admitted to hospital</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>None</p>
<p>(one adverse event not related to study)</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Single&#x02010;arm study</p>
<p>Sample size</p>
<p>Study duration</p>
<p>Intention to treat analysis</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>+ 21.8% (95% CI 10.4&#x02010;33.1)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;&#x000b7;0004</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>No significant change</p>
<p>Control 0 (IQR 0&#x02010;2.7), HCL 0 (IQR 0&#x02010;0.4)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.35</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02212;19.0% (95% CI &#x02212;4.7 to &#x02212;33.3)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.011</p>
</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Bally et al. (2018)<xref rid="dom15920-bib-0124" ref-type="bibr">
<sup>124</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0004"><list-item id="dom15920-li-0016"><p>3&#x02009;mo</p></list-item><list-item id="dom15920-li-0017"><p>136 adults with T2D on insulin</p></list-item><list-item id="dom15920-li-0018"><p>UK and Switzerland</p></list-item><list-item id="dom15920-li-0019"><p>Randomized trial HCL (<italic toggle="yes">n</italic>&#x02009;=&#x02009;70) versus SC insulin</p></list-item><list-item id="dom15920-li-0020"><p>Inpatient hyperglycaemia requiring SC insulin</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>FCL</p>
<p>Dana&#x02010;R with MPC algorithm</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Two&#x02010;centre multi&#x02010;national inpatient, open&#x02010;label study comparing HCL with standard insulin therapy</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % Time in target range (5.6&#x02010;10&#x02009;mmol/L [100&#x02010;180&#x02009;mg/dL])</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 100&#x02013;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 180&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1">No change TDD insulin</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>87% happy to have automated control</p>
<p>98% would recommend the system to a friend or family member if admitted to hospital</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Nil serious</p>
<p>3 FCL group; 2 sensor failure and 1 pump check error</p>
<p>3 control; bruising at cannula site and skin irritation</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Study duration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>+24.3&#x02009;&#x000b1;&#x02009;2.9 (95% CI 18.6&#x02010;30.0)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>No significant change</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.80</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02212;25.9&#x02009;&#x000b1;&#x02009;3.4 (95% CI &#x02212;19.2 to &#x02212;32.7)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.001</p>
</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Boughton et al. (2021)<xref rid="dom15920-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0005"><list-item id="dom15920-li-0021"><p>20&#x02009;d&#x02009;&#x000d7;&#x02009;2</p></list-item><list-item id="dom15920-li-0022"><p>26 adults with T2D requiring dialysis for 6&#x02009;y)</p></list-item><list-item id="dom15920-li-0023"><p>United States</p></list-item><list-item id="dom15920-li-0024"><p>Randomized crossover trial</p></list-item><list-item id="dom15920-li-0025"><p>ESRF on peritoneal&#x02010; or haemo&#x02010;dialysis</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>FCL</p>
<p>CamAPS HX</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Open&#x02010;label, multinational, two&#x02010;centre study to evaluate safety and efficacy of FCL versus standard therapy</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % Time in target range (5.6&#x02010;10&#x02009;mmol/L [100&#x02010;180&#x02009;mg/dL])</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 5.6&#x02010;10&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;3.9&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 10&#x02009;mmol/L</td><td rowspan="2" align="left" valign="top" colspan="1"/><td rowspan="2" align="left" valign="top" colspan="1">
<p>More personal time and freedom improved peace of mind and reassurance</p>
<p>Device burden (discomfort, wearing pump, carrying phone) were the most common limitations</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">One severe hypo&#x02010;glycaemia during closed loop</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Single&#x02010;arm study</p>
<p>Sample size</p>
<p>Study duration</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>15.1% (95% CI 8.0&#x02010;22.2)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Reduced to 0.12 (IQR 0.02&#x02010;0.44) from 0.17 (IQR 0.00&#x02010;1.11)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.04</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>Reduced from 56.6&#x02009;&#x000b1;&#x02009;25.1 to 42.6&#x02009;&#x000b1;&#x02009;14.3</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.003</p>
</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Daly et al. (2023)<xref rid="dom15920-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0006"><list-item id="dom15920-li-0026"><p>8&#x02009;wk&#x02009;&#x000d7;&#x02009;2</p></list-item><list-item id="dom15920-li-0027"><p>26 adults with T2D</p></list-item><list-item id="dom15920-li-0028"><p>United States</p></list-item><list-item id="dom15920-li-0029"><p>Randomized crossover trial</p></list-item><list-item id="dom15920-li-0030"><p>HbA1c&#x02009;&#x0003c;&#x02009;12% (&#x0003c;&#x02009;108&#x02009;mmol/L)</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>FCL</p>
<p>CamAPS HX</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Open&#x02010;label, single&#x02010;centre, randomized crossover study to determine the benefits of FCL systems in adults with T2D</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % Time in target glucose range (3.9&#x02010;10.0&#x02009;mmol/L [70&#x02010;180&#x02009;mg/dL])</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 5.6&#x02010;10&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;3.9&#x02009;mmol/L</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 180&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1"/><td rowspan="2" align="left" valign="top" colspan="1">
<p>Hypoglycaemia confidence scores and PAID scores similar between interventions</p>
<p>Hypoglycaemia worry score higher following closed&#x02010;loop (15.0 [IQR, 6.5&#x02010;20.0]) versus a median of 9.5 (IQR, 6.0&#x02010;21.0)</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">One serious adverse event related to study procedure; abscess at pump site needing incision and drainage</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Single&#x02010;arm study</p>
<p>Sample size</p>
<p>Study duration</p>
<p>Intention to treat analysis</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>+35.3 (95% CI 28.0&#x02010;42.6)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>No significant change</p>
<p>Closed loop 0.44 (IQR 0.19&#x02010;0.81) Control</p>
<p>0.08 (IQR, 0.00%&#x02010;1.05%)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.43</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>&#x02212;35.2 (95% CI, &#x02212;42.8 to &#x02212;27.5)</p>
<p>
<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;.001</p>
</td></tr><tr><td colspan="12" align="left" valign="top" rowspan="1">CFRD</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Scully et al. (2022)<xref rid="dom15920-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0007"><list-item id="dom15920-li-0031"><p>3&#x02009;mo</p></list-item><list-item id="dom15920-li-0032"><p>13 adults and adolescents with CFRD (age 15&#x02010;64.6&#x02009;y) on MDI or insulin pump</p></list-item><list-item id="dom15920-li-0033"><p>United States</p></list-item><list-item id="dom15920-li-0034"><p>Retrospective analysis</p></list-item><list-item id="dom15920-li-0035"><p>Using Dexcom CGM</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>HCL</p>
<p>Tandem T:Slim &#x000d7;&#x02009;2 with Control IQ</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">Multicentre retrospective observational study assessing outcomes post&#x02010;HCL initiation at 1 and 3&#x02009;mo</td><td rowspan="2" align="left" valign="top" colspan="1">&#x025b3; % time in target range 70&#x02010;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 70&#x02010;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 250&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1"/><td rowspan="2" align="left" valign="top" colspan="1">Not assessed</td><td rowspan="2" align="left" valign="top" colspan="1">Not reported</td><td rowspan="2" align="left" valign="top" colspan="1">Sample size</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>69.5&#x02009;&#x000b1;&#x02009;5.1 at 3&#x02009;mo from 54.3&#x02009;&#x000b1;&#x02009;5.1</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>0.3&#x02009;&#x000b1;&#x02009;0.1 at 3&#x02009;mo from 0.2&#x02009;&#x000b1;&#x02009;0.1 at baseline</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.349</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>8.6%&#x02009;&#x000b1;&#x02009;4.6% from 21.1%&#x02009;&#x000b1;&#x02009;4.5% at baseline</p>
<p>
<italic toggle="yes">P</italic>&#x02009;=&#x02009;.008</p>
</td></tr><tr><td rowspan="2" align="left" style="padding-left:10%" valign="top" colspan="1">Sherwood et al. (2020)<xref rid="dom15920-bib-0121" ref-type="bibr">
<sup>121</sup>
</xref>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="roman-lower" id="dom15920-list-0008"><list-item id="dom15920-li-0036"><p>1&#x02009;wk</p></list-item><list-item id="dom15920-li-0037"><p>3 aged &#x02265;&#x02009;18 y with CFRD and</p></list-item><list-item id="dom15920-li-0038"><p>United States</p></list-item><list-item id="dom15920-li-0039"><p>Pilot</p></list-item><list-item id="dom15920-li-0040"><p>TDD insulin &#x02265;&#x02009;0.1&#x02009;u/kg/d</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">HCL or bi&#x02010;hormonal closed loop</td><td rowspan="2" align="left" valign="top" colspan="1">Three&#x02010;arm, random&#x02010;order, crossover pilot study comparing HCL, BH closed loop and SC</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>&#x025b3; mean CGM</p>
<p>&#x025b3; % time below 3&#x02009;mmol/L</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; 70&#x02010;180&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time&#x02009;&#x0003c;&#x02009;54&#x02009;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x025b3; % time &#x0003e; 250&#x02009;mg/dL</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Mean CGM glucose mg/dL</p>
<p>SC 159&#x02009;&#x000b1;&#x02009;35</p>
<p>HCL 149&#x02009;&#x000b1;&#x02009;10</p>
<p>BH 139&#x02009;&#x000b1;&#x02009;15</p>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<p>Management burden and time spent thinking about diabetes reduced with closed loop.</p>
<p>Freer with food choices and overall greater peace of mind</p>
</td><td rowspan="2" align="left" valign="top" colspan="1"/><td rowspan="2" align="left" valign="top" colspan="1">Small sample size</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>SC 62&#x02009;&#x000b1;&#x02009;23</p>
<p>HCL 76&#x02009;&#x000b1;&#x02009;9</p>
<p>BH 80&#x02009;&#x000b1;&#x02009;10</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>SC 0.3&#x02009;&#x000b1;&#x02009;0.3</p>
<p>HCL 0.5&#x02009;&#x000b1;&#x02009;0.1</p>
<p>BH 0.2&#x02009;&#x000b1;&#x02009;0.2</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>SC 9&#x02009;&#x000b1;&#x02009;7</p>
<p>HCL 5&#x02009;&#x000b1;&#x02009;2</p>
<p>BH 4&#x02009;&#x000b1;&#x02009;4</p>
</td></tr></tbody></table><table-wrap-foot id="dom15920-ntgp-0003"><fn id="dom15920-note-0005"><p>
<italic toggle="yes">Note</italic>: Changes to % times in range are represented as either mean&#x02009;&#x000b1;&#x02009;SD, mean (95% CI) or median (IQR).</p></fn><fn id="dom15920-note-0006"><p>Abbreviations: AID, automated insulin delivery; BH, bi&#x02010;hormonal; CFRD, cystic fibrosis&#x02010;related diabetes; CGM, continuous glucose monitor; CI, confidence interval; DIDS, diabetes impact and device satisfaction scale; ESRF, end&#x02010;stage renal failure; FCL, fully closed&#x02010;loop; HCL, hybrid closed&#x02010;loop; IQR, interquartile range; MDI, multiple daily injections; MPC, model predictive control; PAID, problem areas in diabetes scores; PROMIS, patient&#x02010;reported outcomes measurement information system; SC, standard care; SD, standard deviation; TDD, total daily dose; TIR, time in range; T2D, type 2 diabetes.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="dom15920-sec-0018"><label>6</label><title>MAXIMIZING OPPORTUNITIES</title><sec id="dom15920-sec-0019"><label>6.1</label><title>Form factor</title><p>HCL systems with a secondary handset (smartphone or controller) interface may be more easily operated by those with limited dexterity or vision. However, these devices might lack the specific algorithmic features the user desires.</p><p>Similarly, the physical attributes of certain HCL systems may garner increased interest and demand from people with diabetes, irrespective of algorithmic performance; and may explain the rising popularity of the first tubeless HCL system, the OP5. The limited reservoir size of the OP5 may limit its practical use to those with lower daily insulin demands, because individuals with very high daily insulin requirements need to change their pods more frequently, or use more concentrated (U200) insulins (with attendant potential risks).</p></sec><sec id="dom15920-sec-0020"><label>6.2</label><title>Financial</title><p>Clinical trial and real&#x02010;world data led to a technology appraisal of HCL systems for pwT1D in England and Wales at the end of 2023 where a phased implementation of HCL systems to assist in the management of T1D for adults with disabling hypoglycaemia or suboptimal control despite best current management and all children and young people has been mandated within a publicly funded healthcare system.<xref rid="dom15920-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref> Out&#x02010;of&#x02010;pocket costs in European countries vary, and in the United States, where healthcare is insurance based, consensus guidelines recommend that the use of technology should be &#x02018;individualized based on a patient's needs, desires, skill level, and availability of devices&#x02019;<xref rid="dom15920-bib-0126" ref-type="bibr">
<sup>126</sup>
</xref>; individual out&#x02010;of&#x02010;pocket costs are determined by the presence and extent of insurance coverage.</p></sec><sec id="dom15920-sec-0021"><label>6.3</label><title>Deprivation</title><p>National pump audit data in the UK from 2017 to 2018<xref rid="dom15920-bib-0127" ref-type="bibr">
<sup>127</sup>
</xref> and from 2019 to 2020<xref rid="dom15920-bib-0128" ref-type="bibr">
<sup>128</sup>
</xref> reports an inverse relationship between the use and access to insulin pump therapy with socioeconomic quintile, and in T1D care, lower socioeconomic status is associated with poorer diabetes&#x02010;related outcomes.<xref rid="dom15920-bib-0129" ref-type="bibr">
<sup>129</sup>
</xref>, <xref rid="dom15920-bib-0130" ref-type="bibr">
<sup>130</sup>
</xref>, <xref rid="dom15920-bib-0131" ref-type="bibr">
<sup>131</sup>
</xref> With RWE demonstrating that in adults with T1D, access to technology attains equal improvements in glycaemia, irrespective of socioeconomic or ethnic background,<xref rid="dom15920-bib-0132" ref-type="bibr">
<sup>132</sup>
</xref>, <xref rid="dom15920-bib-0133" ref-type="bibr">
<sup>133</sup>
</xref> it is hard to refute a role for inequities in access to technologies as a contributor to the poorer diabetes outcomes observed in those with T1D with lower socio&#x02010;economic status.</p></sec><sec id="dom15920-sec-0022"><label>6.4</label><title>Education</title><p>For patients starting a system, informative discussions with HCPs regarding system suitability and effective troubleshooting are only possible if those HCPs are familiar with available commercial systems; adequate training for HCPs to achieve and maintain this level of knowledge is crucial. Compared with their more affluent counterparts, patients from the most socioeconomically deprived backgrounds report that HCPs display a reduced awareness of available technologies during their discussions with them.<xref rid="dom15920-bib-0134" ref-type="bibr">
<sup>134</sup>
</xref> Confronting the issue of HCP bias to challenge inequities is an area that HCP training can also address. For those living with diabetes, multilingual educational documents (and resources for those with additional hearing, visual, literacy or numerical processing needs) can help to broaden access, and remote training platforms may assist with adapting to and making the best use of newer devices.<xref rid="dom15920-bib-0135" ref-type="bibr">
<sup>135</sup>
</xref>
</p></sec></sec><sec id="dom15920-sec-0023"><label>7</label><title>THE FUTURE</title><sec id="dom15920-sec-0024"><label>7.1</label><title>Single hormone fully closed&#x02010;loop systems</title><p>Single hormone fully closed&#x02010;loop (SHFCL) systems utilize adaptive algorithms that do not require mealtime announcements. A number of small, controlled inpatient<xref rid="dom15920-bib-0123" ref-type="bibr">
<sup>123</sup>
</xref>, <xref rid="dom15920-bib-0124" ref-type="bibr">
<sup>124</sup>
</xref> and outpatient<xref rid="dom15920-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>, <xref rid="dom15920-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> crossover trials have shown the ability of such systems to enhance glycaemic control without increasing the risk of hypoglycaemia in individuals with T2D (Table&#x000a0;<xref rid="dom15920-tbl-0002" ref-type="table">2</xref>). The safety and efficacy of a SHFCL system in the outpatient setting during 8&#x02009;weeks of unrestricted living in 26 adults with T1D has also recently been shown, with improved glycaemia and no severe hypoglycaemia or ketoacidosis.<xref rid="dom15920-bib-0136" ref-type="bibr">
<sup>136</sup>
</xref>
</p></sec><sec id="dom15920-sec-0025"><label>7.2</label><title>Dual hormonal systems</title><p>The outcomes of RCTs assessing the efficacy and safety of dual hormone (DH) systems, largely based on insulin and glucagon, in pwT1D, were recently evaluated in a meta&#x02010;analysis by Zeng et al.<xref rid="dom15920-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> The short studies suggest non&#x02010;inferiority compared with HCL, with practical considerations that also need to be considered. The DARE study, a 12&#x02010;month multicentre RCT in the Netherlands including 240 adults with T1D that aims to determine the glycaemic and QoL impacts and cost efficacy of DH fully closed&#x02010;loop (DHFCL) systems compared with usual care (HCL or SAP), is currently underway.<xref rid="dom15920-bib-0137" ref-type="bibr">
<sup>137</sup>
</xref> Outcomes from this longer duration study may shed light on the comparative clinical efficacy and practicalities of DHFCL systems versus standard care undetected by shorter, smaller studies.</p></sec><sec id="dom15920-sec-0026"><label>7.3</label><title>Sensing different metabolites</title><p>Wolkowicz et al.<xref rid="dom15920-bib-0138" ref-type="bibr">
<sup>138</sup>
</xref> reviewed important analytes that could serve as added inputs to enhance closed&#x02010;loop control in T1D. Incorporation of insulin sensing to provide a true measure of insulin&#x02010;on&#x02010;board, and the integration of a combined continuous glucose&#x02013;ketone monitor, were among those suggested. Further research to assess the accuracy of analyte detection, reliability of communications to control algorithms and the cloud, and the potential for multianalyte&#x02010;detecting sensors to enhance wearability are needed before broader adoption can be considered.</p></sec><sec id="dom15920-sec-0027"><label>7.4</label><title>Additional devices</title><p>DeBoer and colleagues showed that use of the heart rate as an additive input to AID systems via a heart rate monitor triggering an exercise algorithm for glycaemic control reduced the time spent below range during exercise in 18 adolescents with T1D compared with standard HCL systems.<xref rid="dom15920-bib-0139" ref-type="bibr">
<sup>139</sup>
</xref>
</p><p>Alerts from an AI&#x02010;controlled smartwatch app that detects eating behaviour has been shown to improve glycaemic control in pwT1D not using AID systems with a history of missed or late boluses.<xref rid="dom15920-bib-0140" ref-type="bibr">
<sup>140</sup>
</xref> Communication between such applications and a HCL system could improve the accuracy of automated boluses, while communication from the HCL algorithm to smartwatch interface could provide user alerts of automated mealtime boluses; this has the potential to reduce incidences of manual postprandial boluses and subsequent hypoglycaemia risk.</p></sec><sec id="dom15920-sec-0028"><label>7.5</label><title>Artificial intelligence</title><p>AI is increasingly integrated into healthcare data applications. ML is a subset of AI that allows a computer system to learn from experience rather than explicit programming. ML uses an algorithm to analyse and learn from large amounts of data. ML then makes decisions based on its learning to process unseen datasets. ML algorithm performance increases with the amount and diversity of data to which it is exposed.<xref rid="dom15920-bib-0141" ref-type="bibr">
<sup>141</sup>
</xref> A recent pilot feasibility RCT tested the concept of ML to replicate the MPC algorithm in 15 pwT1D.<xref rid="dom15920-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> Outcomes showed that ML was able to produce equivalent outcomes with a 6&#x02010;fold lower computational demand. Results indicate that the use of AI in algorithmic insulin delivery can enhance the battery life of the typically limited&#x02010;power devices in which the control algorithms are commonly situated. Simultaneously, reduced processing power may increase the number of devices that can function as HCL system interfaces.</p></sec><sec id="dom15920-sec-0029"><label>7.6</label><title>Bluetooth</title><p>Bluetooth technology is continually advancing. The earliest form of BLE was Bluetooth 4.0, which was launched in 2010. The faster and more powerful Bluetooth 5.0 was released in 2016, with the most recent Bluetooth 5.4 introducing improvements that include periodic advertising and enhanced encryption, offering security and energy&#x02010;efficiency advantages.</p><p>In 2022, Bluetooth announced a new Bluetooth audio broadcast function called Auracast.<xref rid="dom15920-bib-0142" ref-type="bibr">
<sup>142</sup>
</xref> If integrated to HCL systems, audio&#x02010;controlled insulin delivery could increase the accessibility of systems to those with challenges to literacy or vision. The next major iteration of Bluetooth is Bluetooth 6.0. Details of this system have yet to be released, but it will probably continue improving energy efficiency, security, communication range and speed. Key in upgrades to existing HCL systems is the integration with advancing forms of wireless connectivity to optimize performance.</p></sec></sec><sec id="dom15920-sec-0030"><label>8</label><title>WHAT NEEDS TO BE IMPROVED?</title><sec id="dom15920-sec-0031"><label>8.1</label><title>Interoperability</title><p>With respect to commercial HCL systems, interoperability refers to approved connection between various commercial insulin pumps with CGM devices. It does not refer to adversarial interoperability, otherwise known as competitive compatibility, which is the communication between systems despite the resistance of one or more of the connecting systems.<xref rid="dom15920-bib-0143" ref-type="bibr">
<sup>143</sup>
</xref> Adversarial interoperability allows OS algorithms to connect to a number of commercial insulin pumps and CGM devices, facilitating user choice and personalization (Table&#x000a0;<xref rid="dom15920-tbl-0001" ref-type="table">1</xref>).<xref rid="dom15920-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> In the commercial market, interoperability could offer the same benefits but necessitates commercial agreements between device manufacturers and overcoming regulatory barriers. In August 2017, the JDRF launched the Open Protocol Initiative, aiming to assist in the delivery of interoperable diabetes technologies.<xref rid="dom15920-bib-0144" ref-type="bibr">
<sup>144</sup>
</xref> This was followed by a series of US Food and Drug Administration (FDA) regulations to ensure the safety of such systems<xref rid="dom15920-bib-0145" ref-type="bibr">
<sup>145</sup>
</xref> (Figure&#x000a0;<xref rid="dom15920-fig-0004" ref-type="fig">4</xref>).</p><fig position="float" fig-type="FIGURE" id="dom15920-fig-0004"><label>FIGURE 4</label><caption><p>Cogs in the wheel of interoperability; FDA designations of iCGM, ACE and iAGC statuses have defined regulatory milestones that need to be met before true interoperability between commercial HCL systems can be achieved. ACE, alternate controller&#x02010;enabled; FDA, US Food and Drug Administration; HCL, hybrid closed&#x02010;loop; iAGC, interoperable automated glycaemic controller; iCGM, integrated continuous glucose monitoring.</p></caption><graphic xlink:href="DOM-26-27-g001" position="anchor" id="jats-graphic-7"/></fig><p>In 2018, the FDA defined the &#x02018;integrated continuous glucose monitor&#x02019; (iCGM) that became the first cog in the wheel towards interoperability<xref rid="dom15920-bib-0146" ref-type="bibr">
<sup>146</sup>
</xref> iCGM status is attained when a CGM device meets the FDA's criteria for accuracy and safety. Currently, the Dexcom G6,<xref rid="dom15920-bib-0147" ref-type="bibr">
<sup>147</sup>
</xref> Libre 2, Libre 3 and Eversense<xref rid="dom15920-bib-0148" ref-type="bibr">
<sup>148</sup>
</xref> devices have iCGM status. In 2019, the FDA defined the &#x02018;alternate controller&#x02010;enabled&#x02019; (ACE) pathway<xref rid="dom15920-bib-0145" ref-type="bibr">
<sup>145</sup>
</xref>, <xref rid="dom15920-bib-0149" ref-type="bibr">
<sup>149</sup>
</xref> that became the second cog in the wheel towards interoperability; ACE status is attained when an insulin pump can work safely with multiple algorithms. Tandem's t:slim X2 was the first insulin pump to gain ACE status. In 2020, the FDA defined the &#x02018;interoperable automated glycaemic controller pathway&#x02019;,<xref rid="dom15920-bib-0145" ref-type="bibr">
<sup>145</sup>
</xref>, <xref rid="dom15920-bib-0150" ref-type="bibr">
<sup>150</sup>
</xref> the third and final cog in the wheel towards interoperability; interoperable automated glycaemic controller (iAGC) status is attained when an algorithm can communicate with a number of different insulin pumps and CGM devices.</p><p>One of the most commonly used versions of OS AID is &#x02018;Loop&#x02019; (Table&#x000a0;<xref rid="dom15920-tbl-0001" ref-type="table">1</xref>). In 2018, the not&#x02010;for&#x02010;profit organization, Tidepool, which aims to deliver OS AID technologies, officially launched &#x02018;Tidepool Loop&#x02019;, a project dedicated to &#x02018;delivering an officially supported, FDA regulated version of the Loop app&#x02019;.<xref rid="dom15920-bib-0151" ref-type="bibr">
<sup>151</sup>
</xref> Designation as an iAGC system was a clear aim for Tidepool Loop.<xref rid="dom15920-bib-0145" ref-type="bibr">
<sup>145</sup>
</xref> In January 2023, Tidepool Loop was granted FDA approval<xref rid="dom15920-bib-0152" ref-type="bibr">
<sup>152</sup>
</xref> and became the first OS&#x02010;derived algorithm to achieve this status.<xref rid="dom15920-bib-0153" ref-type="bibr">
<sup>153</sup>
</xref> The commercial launch of the FDA&#x02010;approved HCL system incorporating Tidepool Loop as the twiist AID system is awaited.</p></sec><sec id="dom15920-sec-0032"><label>8.2</label><title>Open standards for AI</title><p>Open standards are rules allowing any user to create compatible and consistent products<xref rid="dom15920-bib-0154" ref-type="bibr">
<sup>154</sup>
</xref> and can assist with AI&#x02010;assisted algorithmic insulin delivery by establishing standards that developers must adhere to. Such standards address issues such as data security, privacy and ownership. The presence of open standards facilitates increased transparency in the processes of algorithm creation. This was probably to improve trust in, and thus enhance the utilization of such systems. Increased use will allow increased data exposure that could facilitate the development of more advanced algorithms. Open standards may also facilitate interoperability.<xref rid="dom15920-bib-0155" ref-type="bibr">
<sup>155</sup>
</xref>
</p><p>An initiative called STANDING Together has released new international consensus standards that aim to balance the benefits of AI in healthcare against the risks of algorithmic bias and harm to those under&#x02010;represented in healthcare datasets.<xref rid="dom15920-bib-0156" ref-type="bibr">
<sup>156</sup>
</xref>, <xref rid="dom15920-bib-0157" ref-type="bibr">
<sup>157</sup>
</xref> These are especially relevant to diabetes technologies<xref rid="dom15920-bib-0158" ref-type="bibr">
<sup>158</sup>
</xref>, <xref rid="dom15920-bib-0159" ref-type="bibr">
<sup>159</sup>
</xref>, <xref rid="dom15920-bib-0160" ref-type="bibr">
<sup>160</sup>
</xref> and diabetes research that<xref rid="dom15920-bib-0161" ref-type="bibr">
<sup>161</sup>
</xref> are less accessible to and less representative of those from minority backgrounds.</p></sec></sec><sec sec-type="conclusions" id="dom15920-sec-0033"><label>9</label><title>CONCLUSIONS</title><p>Establishing connectivity between insulin pumps and CGM devices has enabled significant improvements in diabetes care. The emergence of AID systems, particularly HCLs, has had a significant and positive impact on the lives of people living with T1D. The evidence presented here highlights the potential benefits that these devices can deliver at a population level. Underpinning the success of current AID systems has been Bluetooth connectivity. Advances in engineering will enable better connectivity, which may lead to improved diabetes devices and user experience. It may also enable opportunities to consider connectivity between different combinations of devices and integrate data from different sources for improved outcomes. Future work may overcome the challenges in connectivity and interoperability and define standards for AI and information exchange between diabetes devices.</p></sec><sec id="dom15920-sec-1035"><title>AUTHOR CONTRIBUTIONS</title><p>AA and SH have equally contributed to the design, draft and review of the article. Both AA and SH have approved the version of the article to be published.</p></sec><sec id="dom15920-sec-0035"><title>FUNDING INFORMATION</title><p>SH is a recipient of the Medical Research Council Clinical Academic Partnership award (MR/W030004/1). AA is supported by an unrestricted educational grant from Abbott UK, awarded to SH.</p></sec><sec sec-type="COI-statement" id="dom15920-sec-0036"><title>CONFLICT OF INTEREST STATEMENT</title><p>AA has no conflicts of interest to declare. SH has served on advisory boards for Tandem, Dexcom and Medtronic; has undertaken non&#x02010;promotional educational and/or consultancy work for Abbott UK, Insulet, Dexcom and Roche; and has received an unrestricted educational research grant from Abbott UK and an investigator&#x02010;initiated research grant from Insulet.</p></sec><sec id="dom15920-sec-0037"><sec disp-level="2" id="dom15920-sec-0039"><title>PEER REVIEW</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15920" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15920</ext-link>.</p></sec></sec></body><back><ack id="dom15920-sec-0034"><title>ACKNOWLEDGEMENTS</title><p>This article was commissioned by the editor as part of a Special Supplement made possible by Abbott. Sponsor identity was not disclosed to the authors prior to publication. The authors would like to thank Mr Kia Mir Sanaei for an insightful discussion on the general principles of Bluetooth device connectivity.</p></ack><sec sec-type="data-availability" id="dom15920-sec-0038"><title>DATA AVAILABILITY STATEMENT</title><p>Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><ref-list id="dom15920-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom15920-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom15920-cit-0001">
<string-name>
<surname>Foster</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>KM</given-names>
</string-name>, et al. <article-title>State of type 1 diabetes management and outcomes from the T1D exchange in 2016&#x02010;2018</article-title>. <source>Diabetes Technol Ther</source>. <year>2019</year>;<volume>21</volume>(<issue>2</issue>):<fpage>66</fpage>&#x02010;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2018.0384</pub-id>
<pub-id pub-id-type="pmid">30657336</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0002">
<collab collab-type="authors">NHS Digital</collab>
. <article-title>National Diabetes Audit 2021&#x02010;22, type 1 Diabetes &#x02013; overview</article-title>. Accessed June 24, 2024. <ext-link xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit-type-1-diabetes/nda-type-1-2021-22-overview" ext-link-type="uri">https://digital.nhs.uk/data&#x02010;and&#x02010;information/publications/statistical/national&#x02010;diabetes&#x02010;audit&#x02010;type&#x02010;1&#x02010;diabetes/nda&#x02010;type&#x02010;1&#x02010;2021&#x02010;22&#x02010;overview</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom15920-cit-0003">
<string-name>
<surname>Kadish</surname>
<given-names>AH</given-names>
</string-name>. <article-title>Automation control of blood sugar a servomechanism for glucose monitoring and control</article-title>. <source>Trans Am Soc Artif Intern Organs</source>. <year>1963</year>;<volume>9</volume>(<issue>1</issue>):<fpage>363</fpage>&#x02010;<lpage>367</lpage>.<pub-id pub-id-type="pmid">13958209</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom15920-cit-0004">
<string-name>
<surname>Albisser</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Leibel</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Ewart</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Davidovac</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Botz</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Zingg</surname>
<given-names>W</given-names>
</string-name>. <article-title>An artificial endocrine pancreas</article-title>. <source>Diabetes</source>. <year>1974</year>;<volume>23</volume>(<issue>5</issue>):<fpage>389</fpage>&#x02010;<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.23.5.389</pub-id>
<pub-id pub-id-type="pmid">4598089</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom15920-cit-0005">
<string-name>
<surname>Albisser</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Leibel</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Ewart</surname>
<given-names>TG</given-names>
</string-name>, et al. <article-title>Clinical control of diabetes by the artificial pancreas</article-title>. <source>Diabetes</source>. <year>1974</year>;<volume>23</volume>(<issue>5</issue>):<fpage>397</fpage>&#x02010;<lpage>404</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.23.5.397</pub-id>
<pub-id pub-id-type="pmid">4598090</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom15920-cit-0006">
<string-name>
<surname>Pfeiffer</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Thum</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Clemens</surname>
<given-names>AH</given-names>
</string-name>. <article-title>The artificial beta cell&#x02013;a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system)</article-title>. <source>Horm Metab Res</source>. <year>1974</year>;<volume>6</volume>(<issue>5</issue>):<fpage>339</fpage>&#x02010;<lpage>342</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0028-1093841</pub-id>
<pub-id pub-id-type="pmid">4607598</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom15920-cit-0007">
<string-name>
<surname>Clemens</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>RW</given-names>
</string-name>. <article-title>The development of biostator, a glucose controlled insulin infusion system (GCIIS)</article-title>. <source>Horm Metab Res</source>. <year>1977</year>;<volume>Suppl 7</volume>:<fpage>23</fpage>&#x02010;<lpage>33</lpage>.</mixed-citation></ref><ref id="dom15920-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom15920-cit-0008">
<string-name>
<surname>Slama</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hautecouverture</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Assan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tchobroutsky</surname>
<given-names>G</given-names>
</string-name>. <article-title>One to five days of continuous intravenous insulin infusion on seven diabetic patients</article-title>. <source>Diabetes</source>. <year>1974</year>;<volume>23</volume>(<issue>9</issue>):<fpage>732</fpage>&#x02010;<lpage>738</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.23.9.732</pub-id>
<pub-id pub-id-type="pmid">4414927</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom15920-cit-0009">
<string-name>
<surname>Shichiri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kawamori</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hakui</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yamasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>H</given-names>
</string-name>. <article-title>Closed&#x02010;loop glycemic control with a wearable artificial endocrine pancreas. Variations in daily insulin requirements to glycemic response</article-title>. <source>Diabetes</source>. <year>1984</year>;<volume>33</volume>(<issue>12</issue>):<fpage>1200</fpage>&#x02010;<lpage>1202</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.33.12.1200</pub-id>
<pub-id pub-id-type="pmid">6389235</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom15920-cit-0010">
<string-name>
<surname>Pickup</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Keen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Parsons</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</string-name>. <article-title>Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia</article-title>. <source>Br Med J</source>. <year>1978</year>;<volume>1</volume>(<issue>6107</issue>):<fpage>204</fpage>&#x02010;<lpage>207</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.1.6107.204</pub-id>
<pub-id pub-id-type="pmid">340000</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom15920-cit-0011">
<string-name>
<surname>Tamborlane</surname>
<given-names>WV</given-names>
</string-name>, <string-name>
<surname>Sherwin</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Genel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Felig</surname>
<given-names>P</given-names>
</string-name>. <article-title>Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump</article-title>. <source>N Engl J Med</source>. <year>1979</year>;<volume>300</volume>(<issue>11</issue>):<fpage>573</fpage>&#x02010;<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM197903153001101</pub-id>
<pub-id pub-id-type="pmid">763270</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom15920-cit-0012">
<string-name>
<surname>Champion</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Rodger</surname>
<given-names>NW</given-names>
</string-name>, <string-name>
<surname>Dupre</surname>
<given-names>J</given-names>
</string-name>. <article-title>Continuous subcutaneous infusion of insulin in the management of diabetes mellitus</article-title>. <source>Diabetes</source>. <year>1980</year>;<volume>29</volume>(<issue>3</issue>):<fpage>206</fpage>&#x02010;<lpage>212</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.29.3.206</pub-id>
<pub-id pub-id-type="pmid">6991323</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom15920-cit-0013">
<string-name>
<surname>Home</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Capaldo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Burrin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Worth</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alberti</surname>
<given-names>KG</given-names>
</string-name>. <article-title>A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin&#x02010;dependent diabetic subjects: improved control with CSII</article-title>. <source>Diabetes Care</source>. <year>1982</year>;<volume>5</volume>(<issue>5</issue>):<fpage>466</fpage>&#x02010;<lpage>471</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diacare.5.5.466</pub-id>
<pub-id pub-id-type="pmid">6765222</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom15920-cit-0014">
<string-name>
<surname>Reeves</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Seigler</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Skyler</surname>
<given-names>JS</given-names>
</string-name>. <article-title>Glycemic control in insulin&#x02010;dependent diabetes mellitus. Comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion</article-title>. <source>Am J Med.</source>
<year>1982</year>;<volume>72</volume>(<issue>4</issue>):<fpage>673</fpage>&#x02010;<lpage>680</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0002-9343(82)90479-x</pub-id>
<pub-id pub-id-type="pmid">7041646</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom15920-cit-0015">
<string-name>
<surname>Schiffrin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Belmonte</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one&#x02010;year prospective study</article-title>. <source>Diabetes</source>. <year>1982</year>;<volume>31</volume>(<issue>3</issue>):<fpage>255</fpage>&#x02010;<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diab.31.3.255</pub-id>
<pub-id pub-id-type="pmid">6759242</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom15920-cit-0016">
<string-name>
<surname>Mecklenburg</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Benson</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>NM</given-names>
</string-name>, et al. <article-title>Clinical use of the insulin infusion pump in 100 patients with type I diabetes</article-title>. <source>N Engl J Med</source>. <year>1982</year>;<volume>307</volume>(<issue>9</issue>):<fpage>513</fpage>&#x02010;<lpage>518</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM198208263070901</pub-id>
<pub-id pub-id-type="pmid">7099222</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0017">
<collab collab-type="authors">Novonordisk</collab>
. <article-title>Insulin 100</article-title>. Accesed July 1, 2024. <ext-link xlink:href="https://www.novonordisk.ca/insulin-100/insulin-100-year-timeline.html" ext-link-type="uri">https://www.novonordisk.ca/insulin-100/insulin-100-year-timeline.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0018">
<collab collab-type="authors">Juvenille Diabetes Research Foundation</collab>
. <article-title>100&#x02009;years of insulin</article-title>. Accessed July 1, 2024.&#x000a0;<ext-link xlink:href="https://jdrf.ca/insulin100/" ext-link-type="uri">https://jdrf.ca/insulin100/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom15920-cit-0019">
<string-name>
<surname>Alsaleh</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Keady</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>KMG</given-names>
</string-name>. <article-title>Insulin pumps: from inception to the present and toward the future</article-title>. <source>J Clin Pharm Ther</source>. <year>2010</year>;<volume>35</volume>(<issue>2</issue>):<fpage>127</fpage>&#x02010;<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2710.2009.01048.x</pub-id>
<pub-id pub-id-type="pmid">20456732</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom15920-cit-0020">
<string-name>
<surname>Hirsch</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Farkas&#x02010;Hirsch</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>McGill</surname>
<given-names>JB</given-names>
</string-name>. <article-title>Catheter obstruction with continuous subcutaneous insulin infusion. Effect of insulin concentration</article-title>. <source>Diabetes Care</source>. <year>1992</year>;<volume>15</volume>(<issue>4</issue>):<fpage>593</fpage>&#x02010;<lpage>594</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diacare.15.4.593</pub-id>
<pub-id pub-id-type="pmid">1499492</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom15920-cit-0021">
<string-name>
<surname>Chantelau</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Spraul</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;hlhauser</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gause</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>M</given-names>
</string-name>. <article-title>Long&#x02010;term safety, efficacy and side&#x02010;effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin&#x02010;dependent) diabetes mellitus: a one centre experience</article-title>. <source>Diabetologia</source>. <year>1989</year>;<volume>32</volume>(<issue>7</issue>):<fpage>421</fpage>&#x02010;<lpage>426</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00271261</pub-id>
<pub-id pub-id-type="pmid">2509271</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom15920-cit-0022">
<string-name>
<surname>Mecklenburg</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Guinn</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Sannar</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Blumenstein</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Malfunction of continuous subcutaneous insulin infusion systems: a one&#x02010;year prospective study of 127 patients</article-title>. <source>Diabetes Care</source>. <year>1986</year>;<volume>9</volume>(<issue>4</issue>):<fpage>351</fpage>&#x02010;<lpage>355</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diacare.9.4.351</pub-id>
<pub-id pub-id-type="pmid">3743310</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom15920-cit-0023">
<string-name>
<surname>Peden</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Braaten</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>McKendry</surname>
<given-names>JB</given-names>
</string-name>. <article-title>Diabetic ketoacidosis during long&#x02010;term treatment with continuous subcutaneous insulin infusion</article-title>. <source>Diabetes Care</source>. <year>1984</year>;<volume>7</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02010;<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diacare.7.1.1</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom15920-cit-0024">
<string-name>
<surname>Gross</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Einhorn</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Performance evaluation of the MiniMed&#x000ae; continuous glucose monitoring system during patient Home use</article-title>. <source>Diabetes Technol Ther</source>. <year>2000</year>;<volume>2</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02010;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1089/152091500316737</pub-id>
<pub-id pub-id-type="pmid">11467320</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0025"><label>25</label><mixed-citation publication-type="book" id="dom15920-cit-0025">
<string-name>
<surname>Hirsch</surname>
<given-names>I</given-names>
</string-name>. <part-title>Introduction: history of glucose monitoring</part-title>. <source>Role of Continuous Glucose Monitoring in Diabetes Treatment</source>. <publisher-name>American Diabetes Association</publisher-name>; <year>2018</year>. doi:<pub-id pub-id-type="doi">10.2337/db20181-1</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0026">
<collab collab-type="authors">Diabetes UK</collab>
. <article-title>CGM: Medtronic Guardian REAL&#x02010;time system</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.diabetes.co.uk/cgm/medtronic-guardian-real-time.html" ext-link-type="uri">https://www.diabetes.co.uk/cgm/medtronic-guardian-real-time.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0027">
<collab collab-type="authors">Food and Drug Administration</collab>
. <article-title>DexCom STS continuous glucose monitoring system</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.accessdata.fda.gov/cdrh_docs/pdf5/p050012b.Pdf" ext-link-type="uri">https://www.accessdata.fda.gov/cdrh_docs/pdf5/p050012b.Pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0028">
<article-title>CGM: Freestyle Navigator. Diabetes UK</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.diabetes.co.uk/cgm/freestyle-navigator-cgm.html" ext-link-type="uri">https://www.diabetes.co.uk/cgm/freestyle-navigator-cgm.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom15920-cit-0029">
<string-name>
<surname>Link</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kamecke</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Waldenmaier</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Comparative accuracy analysis of a real&#x02010;time and an intermittent&#x02010;scanning continuous glucose monitoring system</article-title>. <source>J Diabetes Sci Technol</source>. <year>2021</year>;<volume>15</volume>(<issue>2</issue>):<fpage>287</fpage>&#x02010;<lpage>293</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1932296819895022</pub-id>
<pub-id pub-id-type="pmid">31847555</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom15920-cit-0030">
<string-name>
<surname>Skyler</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ponder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kruger</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Matheson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parkin</surname>
<given-names>CG</given-names>
</string-name>. <article-title>Is there a place for insulin pump therapy in your practice?</article-title>
<source>Clinical Diabetes</source>. <year>2007</year>;<volume>25</volume>(<issue>2</issue>):<fpage>50</fpage>&#x02010;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.2337/diaclin.25.2.50</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom15920-cit-0031">
<string-name>
<surname>Kowalski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lum</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Juvenile diabetes research foundation artificial pancreas consortium update</article-title>. <source>J Diabetes Sci Technol</source>. <year>2009</year>;<volume>3</volume>(<issue>5</issue>):<fpage>1224</fpage>&#x02010;<lpage>1226</lpage>. doi:<pub-id pub-id-type="doi">10.1177/193229680900300531</pub-id>
<pub-id pub-id-type="pmid">20144441</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom15920-cit-0032">
<string-name>
<surname>Kowalski</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes</article-title>. <source>Diabetes Technol Ther</source>. <year>2009</year>;<volume>11</volume>(<issue>S1</issue>):<fpage>S&#x02010;113</fpage>&#x02010;<lpage>S&#x02010;119</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2009.0031</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom15920-cit-0033">
<string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Klonoff</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>SK</given-names>
</string-name>, et al. <article-title>Threshold&#x02010;based insulin&#x02010;pump interruption for reduction of hypoglycemia</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>(<issue>3</issue>):<fpage>224</fpage>&#x02010;<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1303576</pub-id>
<pub-id pub-id-type="pmid">23789889</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0034"><label>34</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0034">
<collab collab-type="authors">Medtronic</collab>
. <article-title>Innovation Milestones</article-title>. Accessed May 31, 2024. <ext-link xlink:href="https://www.medtronicdiabetes.com/about-medtronic-innovation/milestone-timeline" ext-link-type="uri">https://www.medtronicdiabetes.com/about&#x02010;medtronic&#x02010;innovation/milestone&#x02010;timeline</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom15920-cit-0035">
<string-name>
<surname>Forlenza</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Buckingham</surname>
<given-names>BA</given-names>
</string-name>, et al. <article-title>Predictive low&#x02010;glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at&#x02010;home randomized crossover study: results of the PROLOG trial</article-title>. <source>Diabetes Care</source>. <year>2018</year>;<volume>41</volume>(<issue>10</issue>):<fpage>2155</fpage>&#x02010;<lpage>2161</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc18-0771</pub-id>
<pub-id pub-id-type="pmid">30089663</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0036">
<collab collab-type="authors">NICE: National Institute for Clinical Excellence</collab>
. <article-title>MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.nice.org.uk/advice/mib51/resources/minimed-640g-system-with-smartguard-for-managing-blood-glucose-levels-in-people-with-type-1-diabetes-pdf-63499221488581" ext-link-type="uri">https://www.nice.org.uk/advice/mib51/resources/minimed&#x02010;640g&#x02010;system&#x02010;with&#x02010;smartguard&#x02010;for&#x02010;managing&#x02010;blood&#x02010;glucose&#x02010;levels&#x02010;in&#x02010;people&#x02010;with&#x02010;type&#x02010;1&#x02010;diabetes&#x02010;pdf&#x02010;63499221488581</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dom15920-cit-0037">
<string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kumareswaran</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>342</volume>:<elocation-id>d1855</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmj.d1855</pub-id>
<pub-id pub-id-type="pmid">21493665</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dom15920-cit-0038">
<string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chassin</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Wilinska</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>Closing the loop: the adicol experience</article-title>. <source>Diabetes Technol Ther</source>. <year>2004</year>;<volume>6</volume>(<issue>3</issue>):<fpage>307</fpage>&#x02010;<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1089/152091504774197990</pub-id>
<pub-id pub-id-type="pmid">15198833</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dom15920-cit-0039">
<string-name>
<surname>Jennings</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>S</given-names>
</string-name>. <article-title>Do&#x02010;it&#x02010;yourself artificial pancreas systems: a review of the emerging evidence and insights for healthcare professionals</article-title>. <source>J Diabetes Sci Technol</source>. <year>2020</year>;<volume>14</volume>(<issue>5</issue>):<fpage>868</fpage>&#x02010;<lpage>877</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1932296819894296</pub-id>
<pub-id pub-id-type="pmid">31847570</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dom15920-cit-0040">
<string-name>
<surname>Braune</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lal</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Petru&#x0017e;elkov&#x000e1;</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Open&#x02010;source automated insulin delivery: international consensus statement and practical guidance for health&#x02010;care professionals</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2022</year>;<volume>10</volume>(<issue>1</issue>):<fpage>58</fpage>&#x02010;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(21)00267-9</pub-id>
<pub-id pub-id-type="pmid">34785000</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="dom15920-cit-0041">
<string-name>
<surname>Garg</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Weinzimer</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Tamborlane</surname>
<given-names>WV</given-names>
</string-name>, et al. <article-title>Glucose outcomes with the in&#x02010;Home use of a hybrid closed&#x02010;loop insulin delivery system in adolescents and adults with type 1 diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2017</year>;<volume>19</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02010;<lpage>163</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2016.0421</pub-id>
<pub-id pub-id-type="pmid">28134564</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dom15920-cit-0042">
<string-name>
<surname>Peacock</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Frizelle</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>S</given-names>
</string-name>. <article-title>A systematic review of commercial hybrid closed&#x02010;loop automated insulin delivery systems</article-title>. <source>Diabetes Ther</source>. <year>2023</year>;<volume>14</volume>(<issue>5</issue>):<fpage>839</fpage>&#x02010;<lpage>855</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13300-023-01394-5</pub-id>
<pub-id pub-id-type="pmid">37017916</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dom15920-cit-0043">
<string-name>
<surname>Lewis</surname>
<given-names>D</given-names>
</string-name>. <article-title>History and perspective on DIY closed looping</article-title>. <source>J Diabetes Sci Technol</source>. <year>2019</year>;<volume>13</volume>(<issue>4</issue>):<fpage>790</fpage>&#x02010;<lpage>793</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1932296818808307</pub-id>
<pub-id pub-id-type="pmid">30348013</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0044"><label>44</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0044">
<collab collab-type="authors">iAPS Community</collab>
. <article-title>iAPS</article-title>. <year>2024</year> Accessed July 29, 2024. <ext-link xlink:href="https://iaps.readthedocs.io/en/main/settings/devices/cgm.html" ext-link-type="uri">https://iaps.readthedocs.io/en/main/settings/devices/cgm.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0045"><label>45</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0045">
<collab collab-type="authors">Trio</collab>
. <article-title>What is trio?</article-title>
<year>2024</year> Accessed July 3, 2024. <ext-link xlink:href="https://oidocs-mikeplante1.readthedocs.io/en/latest/" ext-link-type="uri">https://oidocs-mikeplante1.readthedocs.io/en/latest/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0046"><label>46</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0046">
<collab collab-type="authors">BetaBionics</collab>
. <article-title>iLet bionic pancreas system user guide</article-title>
<year>2024</year>. Accessed July 3, 2024. <ext-link xlink:href="https://www.betabionics.com/wp-content/uploads/LA000081_E_iLet-Bionic-Pancreas-System-User-Guide.pdf" ext-link-type="uri">https://www.betabionics.com/wp-content/uploads/LA000081_E_iLet-Bionic-Pancreas-System-User-Guide.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0047"><label>47</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0047">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>ADA Consumer Guide: iLet Bionic Pancreas System. American Diabetes Association</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://consumerguide.diabetes.org/products/ilet-bionic-pancreas-system" ext-link-type="uri">https://consumerguide.diabetes.org/products/ilet-bionic-pancreas-system</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0048"><label>48</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0048">
<collab collab-type="authors">Open APS</collab>
. <article-title>Understanding the determine&#x02010;basal logic</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://openaps.readthedocs.io/en/latest/docs/While%20You%20Wait%20For%20Gear/Understand-determine-basal.html#:~:text=The%20OpenAPS%20reference%20design%20algorithm,without%20(much)%20carb%20absorption" ext-link-type="uri">https://openaps.readthedocs.io/en/latest/docs/While%20You%20Wait%20For%20Gear/Understand&#x02010;determine&#x02010;basal.html#:~:text=The%20OpenAPS%20reference%20design%20algorithm,without%20(much)%20carb%20absorption</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0049"><label>49</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0049">
<collab collab-type="authors">Bluetooth SIG</collab>
. <article-title>TECHNOLOGY Understanding Bluetooth Range: What is the Range of Bluetooth&#x000ae; Technology?</article-title> Accessed July 3, 2024. <ext-link xlink:href="https://www.bluetooth.com/learn-about-bluetooth/key-attributes/range/" ext-link-type="uri">https://www.bluetooth.com/learn-about-bluetooth/key-attributes/range/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0050">
<collab collab-type="authors">C&#x00026;T RF Antennas Inc</collab>
. <article-title>2.4&#x02009;GHz vs Bluetooth wireless technology</article-title>. Accessed July 29, 2024. <ext-link xlink:href="https://www.linkedin.com/pulse/24-ghz-vs-bluetooth-wireless-technology-ct-rf-antennas-inc/" ext-link-type="uri">https://www.linkedin.com/pulse/24-ghz-vs-bluetooth-wireless-technology-ct-rf-antennas-inc/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0051"><label>51</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0051">
<collab collab-type="authors">Wikipedia contributors</collab>
. <article-title>ISM radio band. Wikipedia, the free encyclopedia</article-title>. <year>2024</year> Accessed July 29, 2024. <ext-link xlink:href="https://en.wikipedia.org/w/index.php?title=ISM_radio_band&#x00026;oldid=1232282034" ext-link-type="uri">https://en.wikipedia.org/w/index.php?title=ISM_radio_band&#x00026;oldid=1232282034</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0052"><label>52</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0052">
<collab collab-type="authors">Medtronic</collab>
. <article-title>MiniMed 630G System User Guide</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150001S021c.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150001S021c.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0053"><label>53</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0053">
<collab collab-type="authors">NHS Digital</collab>
. <article-title>Medtronic releases urgent recall for MiniMed MMT&#x02010;500 and MMT&#x02010;503 remote</article-title>. <year>2021</year> Accessed July 3, 2024. <ext-link xlink:href="https://digital.nhs.uk/cyber-alerts/2021/cc-3956" ext-link-type="uri">https://digital.nhs.uk/cyber-alerts/2021/cc-3956</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0054"><label>54</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0054">
<collab collab-type="authors">Medtronic</collab>
. <article-title>URGENT FIELD SAFETY NOTIFICATION MiniMed&#x02122; remote controller(MMT&#x02010;500 or MMT&#x02010;503)</article-title>. <year>2018</year> Accessed July 1, 2024. <ext-link xlink:href="https://asiapac.medtronic.com/content/dam/medtronic-com/products/product-performance/documents/minimed-remote-controller-safety-notification-letter-aug-2018.pdf" ext-link-type="uri">https://asiapac.medtronic.com/content/dam/medtronic&#x02010;com/products/product&#x02010;performance/documents/minimed&#x02010;remote&#x02010;controller&#x02010;safety&#x02010;notification&#x02010;letter&#x02010;aug&#x02010;2018.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0055"><label>55</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0055">
<collab collab-type="authors">Medtronic</collab>
. <article-title>Medtronic 640G System User Guide</article-title>. Accessed July 29, 2024. <ext-link xlink:href="https://hcp.medtronic-diabetes.com.au/sites/default/files/minimed-640g-system-user-guide-mmol.pdf" ext-link-type="uri">https://hcp.medtronic-diabetes.com.au/sites/default/files/minimed-640g-system-user-guide-mmol.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0056"><label>56</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0056">
<collab collab-type="authors">Medtronic</collab>
. <article-title>MiniMed 670G system user guide</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed%20670G%20System%20User%20Guide.pdf" ext-link-type="uri">https://www.medtronicdiabetes.com/sites/default/files/library/download&#x02010;library/user&#x02010;guides/MiniMed%20670G%20System%20User%20Guide.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0057"><label>57</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0057">
<collab collab-type="authors">Medtronic</collab>
. <article-title>MiniMed 780G system user guide (with Guardian 4 sensor). Medtronic</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/MiniMed-780G-system-user-guide-with-Guardian-4-sensor.pdf" ext-link-type="uri">https://www.medtronicdiabetes.com/sites/default/files/library/download&#x02010;library/user&#x02010;guides/MiniMed&#x02010;780G&#x02010;system&#x02010;user&#x02010;guide&#x02010;with&#x02010;Guardian&#x02010;4&#x02010;sensor.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0058"><label>58</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0058">
<collab collab-type="authors">Intel.com</collab>
. <article-title>What is Bluetooth&#x000ae; technology?</article-title> Accessed July 3, 2024. <ext-link xlink:href="https://www.intel.com/content/www/us/en/products/docs/wireless/what-is-bluetooth.html" ext-link-type="uri">https://www.intel.com/content/www/us/en/products/docs/wireless/what&#x02010;is&#x02010;bluetooth.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0059"><label>59</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0059">
<article-title>LEARN ABOUT BLUETOOTH Bluetooth Technology Overview; Bluetooth wireless technology</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://www.bluetooth.com/learn-about-bluetooth/tech-overview/" ext-link-type="uri">https://www.bluetooth.com/learn-about-bluetooth/tech-overview/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="dom15920-cit-0060">
<string-name>
<surname>Hartnell</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fuchs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Boughton</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>. <article-title>Closed&#x02010;loop technology: a practical guide</article-title>. <source>Practical Diabetes</source>. <year>2021</year>;<volume>38</volume>(<issue>4</issue>):<fpage>33</fpage>&#x02010;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pdi.2350</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0061"><label>61</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0061">
<collab collab-type="authors">Dell Technologies; Knowledge Base Article</collab>
. <article-title>How to identify and reduce wireless signal interference summary: wireless signal interference becomes a concern for connection stability and overall performance</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://dell.com/support/kbdoc/en-uk/000150359/how-to-identify-and-reduce-wireless-signal-interference" ext-link-type="uri">https://dell.com/support/kbdoc/en&#x02010;uk/000150359/how&#x02010;to&#x02010;identify&#x02010;and&#x02010;reduce&#x02010;wireless&#x02010;signal&#x02010;interference</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0062"><label>62</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0062">
<collab collab-type="authors">Cadence PCB Solutions</collab>
. <article-title>Interference mitigation techniques in wireless communication systems (blog)</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://resources.pcb.cadence.com/blog/2022-interference-mitigation-techniques-in-wireless-communications-systems" ext-link-type="uri">https://resources.pcb.cadence.com/blog/2022&#x02010;interference&#x02010;mitigation&#x02010;techniques&#x02010;in&#x02010;wireless&#x02010;communications&#x02010;systems</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="dom15920-cit-0063">
<string-name>
<surname>Lal</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Basina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maahs</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Hood</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Buckingham</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>DM</given-names>
</string-name>. <article-title>One year clinical experience of the first commercial hybrid closed&#x02010;loop system</article-title>. <source>Diabetes Care</source>. <year>2019</year>;<volume>42</volume>(<issue>12</issue>):<fpage>2190</fpage>&#x02010;<lpage>2196</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc19-0855</pub-id>
<pub-id pub-id-type="pmid">31548247</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0064"><label>64</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0064">
<collab collab-type="authors">RF Wireless Word</collab>
. <article-title>10 advantages and disadvantages of radio frequency (RF) waves and its uses</article-title>. Accessed July 3, 2024. <ext-link xlink:href="https://www.rfwireless-world.com/Terminology/Advantages-and-Disadvantages-of-RF.html" ext-link-type="uri">https://www.rfwireless&#x02010;world.com/Terminology/Advantages&#x02010;and&#x02010;Disadvantages&#x02010;of&#x02010;RF.html</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0065"><label>65</label><mixed-citation publication-type="book" id="dom15920-cit-0065">
<string-name>
<surname>Pulkkinen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nurminen</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Nurmi</surname>
<given-names>P</given-names>
</string-name>. <part-title>Understanding WiFi cross&#x02010;technology interference detection in the real world</part-title>. <source>2020 IEEE 40th International Conference on Distributed Computing Systems (ICDCS)</source>. IEEE Computer Society Conference Publishing Services;&#x000a0;<year>2020</year>:<fpage>954</fpage>&#x02010;<lpage>964</lpage>. doi:<pub-id pub-id-type="doi">10.1109/ICDCS47774.2020.00061</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0066"><label>66</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0066">
<collab collab-type="authors">Medicine and Healthcare products regulatory agency</collab>
. <article-title>Medical devices: sources of electromagnetic interference (gov.UK)</article-title>. <year>2020</year> Accessed July 1, 2024.</mixed-citation></ref><ref id="dom15920-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="dom15920-cit-0067">
<string-name>
<surname>Hughes</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Kingman</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lal</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Buckingham</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Zaharieva</surname>
<given-names>DP</given-names>
</string-name>. <article-title>Swimming with the Omnipod 5 automated insulin delivery system: connectivity in the water</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>8</issue>):<fpage>e148</fpage>&#x02010;<lpage>e150</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc23-0470</pub-id>
<pub-id pub-id-type="pmid">37311429</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="dom15920-cit-0068">
<string-name>
<surname>Christoe</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Michael</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kalantar&#x02010;Zadeh</surname>
<given-names>K</given-names>
</string-name>. <article-title>Bluetooth signal attenuation analysis in human body tissue analogues</article-title>. <source>IEEE Access</source>. <year>2021</year>;<volume>9</volume>:<fpage>85144</fpage>&#x02010;<lpage>85150</lpage>. doi:<pub-id pub-id-type="doi">10.1109/ACCESS.2021.3087780</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0069"><label>69</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0069">
<collab collab-type="authors">Bluetooth</collab>
. <article-title>How Bluetooth&#x000ae; technology makes wireless communication reliable; how Bluetooth technology overcomes interference</article-title>. Accessed July 2, 2024. <ext-link xlink:href="https://www.bluetooth.com/learn-about-bluetooth/key-attributes/reliability/" ext-link-type="uri">https://www.bluetooth.com/learn-about-bluetooth/key-attributes/reliability/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0070"><label>70</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0070">
<article-title>How Bluetooth Technology Uses Adaptive Frequency Hopping to Overcome Packet Interference</article-title>. Accessed July 1, 2024. <ext-link xlink:href="https://www.bluetooth.com/blog/how-bluetooth-technology-uses-adaptive-frequency-hopping-to-overcome-packet-interference/" ext-link-type="uri">https://www.bluetooth.com/blog/how&#x02010;bluetooth&#x02010;technology&#x02010;uses&#x02010;adaptive&#x02010;frequency&#x02010;hopping&#x02010;to&#x02010;overcome&#x02010;packet&#x02010;interference/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="dom15920-cit-0071">
<string-name>
<surname>Saltzstein</surname>
<given-names>W</given-names>
</string-name>. <article-title>Bluetooth wireless technology cybersecurity and diabetes technology devices</article-title>. <source>J Diabetes Sci Technol</source>. <year>2020</year>;<volume>14</volume>(<issue>6</issue>):<fpage>1111</fpage>&#x02010;<lpage>1115</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1932296819864416</pub-id>
<pub-id pub-id-type="pmid">31319701</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="dom15920-cit-0072">
<string-name>
<surname>Lawton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hart</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Kimbell</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Data sharing while using a closed&#x02010;loop system: qualitative study of adolescents' and parents' experiences and views</article-title>. <source>Diabetes Technol Ther</source>. <year>2021</year>;<volume>23</volume>(<issue>7</issue>):<fpage>500</fpage>&#x02010;<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2020.0637</pub-id>
<pub-id pub-id-type="pmid">33605790</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="dom15920-cit-0073">
<string-name>
<surname>Hart</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Kimbell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rankin</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Parents' experiences of using remote monitoring technology to manage type 1 diabetes in very young children during a clinical trial: qualitative study</article-title>. <source>Diabet Med</source>. <year>2022</year>;<volume>39</volume>(<issue>7</issue>):<elocation-id>e14828</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/dme.14828</pub-id>
<pub-id pub-id-type="pmid">35274356</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="dom15920-cit-0074">
<string-name>
<surname>Kimbell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rankin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hart</surname>
<given-names>RI</given-names>
</string-name>, et al. <article-title>Parents' views about healthcare professionals having real&#x02010;time remote access to their young child's diabetes data: qualitative study</article-title>. <source>Pediatr Diabetes</source>. <year>2022</year>;<volume>23</volume>(<issue>6</issue>):<fpage>799</fpage>&#x02010;<lpage>808</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pedi.13363</pub-id>
<pub-id pub-id-type="pmid">35561092</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="dom15920-cit-0075">
<string-name>
<surname>Fuchs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>. <article-title>COVID&#x02010;19 and diabetes: could diabetes technology research help pave the way for remote healthcare?</article-title>
<source>J Diabetes Sci Technol</source>. <year>2020</year>;<volume>14</volume>(<issue>4</issue>):<fpage>735</fpage>&#x02010;<lpage>736</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1932296820929714</pub-id>
<pub-id pub-id-type="pmid">32475169</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="dom15920-cit-0076">
<string-name>
<surname>Al&#x02010;Issa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ottom</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Tamrawi</surname>
<given-names>A</given-names>
</string-name>. <article-title>eHealth cloud security challenges: a survey</article-title>. <source>J Healthc Eng</source>. <year>2019</year>;<volume>2019</volume>:<elocation-id>7516035</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2019/7516035</pub-id>
<pub-id pub-id-type="pmid">31565209</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="dom15920-cit-0077">
<string-name>
<surname>Hu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>. <article-title>An improved PID algorithm based on insulin&#x02010;on&#x02010;board estimate for Blood glucose control with type 1 diabetes</article-title>. <source>Comput Math Methods Med</source>. <year>2015</year>;<volume>2015</volume>:<elocation-id>281589</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2015/281589</pub-id>
<pub-id pub-id-type="pmid">26550021</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0078"><label>78</label><mixed-citation publication-type="book" id="dom15920-cit-0078">
<string-name>
<surname>Ghorbani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bogdan</surname>
<given-names>P</given-names>
</string-name>. <part-title>Challenges and opportunities in design of control algorithm for artificial pancreas</part-title>. <source>5th Workshop on Medical Cyber&#x02010;Physical Systems</source>. <publisher-name>
<italic toggle="yes">Schloss&#x02010;Dagstuhl&#x02010;Leibniz Zentrum f&#x000fc;r Informatik</italic>
</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="dom15920-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="dom15920-cit-0079">
<string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Canonico</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Chassin</surname>
<given-names>LJ</given-names>
</string-name>, et al. <article-title>Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes</article-title>. <source>Physiol Meas</source>. <year>2004</year>;<volume>25</volume>(<issue>4</issue>):<fpage>905</fpage>&#x02010;<lpage>920</lpage>. doi:<pub-id pub-id-type="doi">10.1088/0967-3334/25/4/010</pub-id>
<pub-id pub-id-type="pmid">15382830</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="dom15920-cit-0080">
<string-name>
<surname>80Boughton</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>. <article-title>Automated insulin delivery in adults</article-title>. <source>Endocrinol Metab Clin North Am</source>. <year>2020</year>;<volume>49</volume>(<issue>1</issue>):<fpage>167</fpage>&#x02010;<lpage>178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ecl.2019.10.007</pub-id>
<pub-id pub-id-type="pmid">31980116</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="dom15920-cit-0081">
<string-name>
<surname>Lakshman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Boughton</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hovorka</surname>
<given-names>R</given-names>
</string-name>. <article-title>The changing landscape of automated insulin delivery in the management of type 1 diabetes</article-title>. <source>Endocr Connect</source>. <year>2023</year>;<volume>12</volume>(<issue>8</issue>):<elocation-id>e230132</elocation-id>. doi:<pub-id pub-id-type="doi">10.1530/EC-23-0132</pub-id>
<pub-id pub-id-type="pmid">37289734</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="dom15920-cit-0082">
<string-name>
<surname>Steil</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Rebrin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Darwin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hariri</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Saad</surname>
<given-names>MF</given-names>
</string-name>. <article-title>Feasibility of automating insulin delivery for the treatment of type 1 diabetes</article-title>. <source>Diabetes</source>. <year>2006</year>;<volume>55</volume>(<issue>12</issue>):<fpage>3344</fpage>&#x02010;<lpage>3350</lpage>. doi:<pub-id pub-id-type="doi">10.2337/db06-0419</pub-id>
<pub-id pub-id-type="pmid">17130478</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="dom15920-cit-0083">
<string-name>
<surname>Atlas</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nimri</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grunberg</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Phillip</surname>
<given-names>M</given-names>
</string-name>. <article-title>MD&#x02010;logic artificial pancreas system: a pilot study in adults with type 1 diabetes</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1072</fpage>&#x02010;<lpage>1076</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc09-1830</pub-id>
<pub-id pub-id-type="pmid">20150292</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="dom15920-cit-0084">
<string-name>
<surname>Boughton</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Tripyla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hartnell</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Fully automated closed&#x02010;loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open&#x02010;label, randomized crossover trial</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1471</fpage>&#x02010;<lpage>1476</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01453-z</pub-id>
<pub-id pub-id-type="pmid">34349267</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="dom15920-cit-0085">
<string-name>
<surname>Daly</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Boughton</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Nwokolo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Fully automated closed&#x02010;loop insulin delivery in adults with type 2 diabetes: an open&#x02010;label, single&#x02010;center, randomized crossover trial</article-title>. <source>Nat Med</source>. <year>2023</year>;<volume>29</volume>(<issue>1</issue>):<fpage>203</fpage>&#x02010;<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-02144-z</pub-id>
<pub-id pub-id-type="pmid">36631592</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="dom15920-cit-0086">
<string-name>
<surname>Kovatchev</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Castillo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pryor</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Neural&#x02010;net artificial pancreas: a randomized crossover trial of a first&#x02010;in&#x02010;class automated insulin delivery algorithm</article-title>. <source>Diabetes Technol Ther</source>. <year>2024</year>;<volume>26</volume>(<issue>6</issue>):<fpage>375</fpage>&#x02010;<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2023.0469</pub-id>
<pub-id pub-id-type="pmid">38277161</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="dom15920-cit-0087">
<string-name>
<surname>Hermanides</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Devries</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Sensor&#x02010;augmented insulin pump more effective than multiple daily insulin injections for reducing HbA1C in people with poorly controlled type 1 diabetes</article-title>. <source>Evid Based Med</source>. <year>2011</year>;<volume>16</volume>(<issue>2</issue>):<fpage>46</fpage>&#x02010;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ebm1159</pub-id>
<pub-id pub-id-type="pmid">21224281</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="dom15920-cit-0088">
<string-name>
<surname>Hermanides</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>N&#x000f8;rgaard</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bruttomesso</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Sensor&#x02010;augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes; a randomized controlled trial</article-title>. <source>Diabet Med</source>. <year>2011</year>;<volume>28</volume>(<issue>10</issue>):<fpage>1158</fpage>&#x02010;<lpage>1167</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1464-5491.2011.03256.x</pub-id>
<pub-id pub-id-type="pmid">21294770</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="dom15920-cit-0089">
<string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Tamborlane</surname>
<given-names>WV</given-names>
</string-name>, <string-name>
<surname>Ahmann</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Effectiveness of sensor&#x02010;augmented insulin&#x02010;pump therapy in type 1 diabetes</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>4</issue>):<fpage>311</fpage>&#x02010;<lpage>320</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1002853</pub-id>
<pub-id pub-id-type="pmid">20587585</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="dom15920-cit-0090">
<string-name>
<surname>O'Connell</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Donath</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>O'Neal</surname>
<given-names>DN</given-names>
</string-name>, et al. <article-title>Glycaemic impact of patient&#x02010;led use of sensor&#x02010;guided pump therapy in type 1 diabetes: a randomised controlled trial</article-title>. <source>Diabetologia</source>. <year>2009</year>;<volume>52</volume>(<issue>7</issue>):<fpage>1250</fpage>&#x02010;<lpage>1257</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00125-009-1365-0</pub-id>
<pub-id pub-id-type="pmid">19396424</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="dom15920-cit-0091">
<string-name>
<surname>Kamble</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Weinfurt</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Reed</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Patient time costs associated with sensor&#x02010;augmented insulin pump therapy for type 1 diabetes</article-title>. <source>Med Decis Making</source>. <year>2013</year>;<volume>33</volume>(<issue>2</issue>):<fpage>215</fpage>&#x02010;<lpage>224</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0272989X12464824</pub-id>
<pub-id pub-id-type="pmid">23128579</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="dom15920-cit-0092">
<string-name>
<surname>Ly</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Nicholas</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Retterath</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>TW</given-names>
</string-name>. <article-title>Effect of sensor&#x02010;augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>(<issue>12</issue>):<fpage>1240</fpage>&#x02010;<lpage>1247</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.277818</pub-id>
<pub-id pub-id-type="pmid">24065010</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="dom15920-cit-0093">
<string-name>
<surname>M&#x000fc;ller</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Habif</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aronoff&#x02010;Spencer</surname>
<given-names>E</given-names>
</string-name>. <article-title>Reducing hypoglycemia in the real world: a retrospective analysis of predictive low&#x02010;glucose suspend technology in an ambulatory insulin&#x02010;dependent cohort</article-title>. <source>Diabetes Technol Ther</source>. <year>2019</year>;<volume>21</volume>(<issue>9</issue>):<fpage>478</fpage>&#x02010;<lpage>484</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2019.0190</pub-id>
<pub-id pub-id-type="pmid">31329468</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="dom15920-cit-0094">
<string-name>
<surname>Beato&#x02010;V&#x000ed;bora</surname>
<given-names>PI</given-names>
</string-name>, <string-name>
<surname>Quir&#x000f3;s&#x02010;L&#x000f3;pez</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>L&#x000e1;zaro&#x02010;Mart&#x000ed;n</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Impact of sensor&#x02010;augmented pump therapy with predictive low&#x02010;glucose suspend function on glycemic control and patient satisfaction in adults and children with type 1 diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2018</year>;<volume>20</volume>(<issue>11</issue>):<fpage>738</fpage>&#x02010;<lpage>743</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2018.0199</pub-id>
<pub-id pub-id-type="pmid">30256132</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="dom15920-cit-0095">
<string-name>
<surname>Biester</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kordonouri</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Holder</surname>
<given-names>M</given-names>
</string-name>, et al. &#x0201c;<article-title>Let the algorithm do the work&#x0201d;: reduction of hypoglycemia using sensor&#x02010;augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients</article-title>. <source>Diabetes Technol Ther</source>. <year>2017</year>;<volume>19</volume>(<issue>3</issue>):<fpage>173</fpage>&#x02010;<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2016.0349</pub-id>
<pub-id pub-id-type="pmid">28099035</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="dom15920-cit-0096">
<string-name>
<surname>Bekiari</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kitsios</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Thabit</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta&#x02010;analysis</article-title>. <source>BMJ</source>. <year>2018</year>;<volume>361</volume>:<elocation-id>k1310</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmj.k1310</pub-id>
<pub-id pub-id-type="pmid">29669716</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="dom15920-cit-0097">
<string-name>
<surname>Pease</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Earnest</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kiriakova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Liew</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Zoungas</surname>
<given-names>S</given-names>
</string-name>. <article-title>Time in range for multiple technologies in type 1 diabetes: a systematic review and network meta&#x02010;analysis</article-title>. <source>Diabetes Care</source>. <year>2020</year>;<volume>43</volume>(<issue>8</issue>):<fpage>1967</fpage>&#x02010;<lpage>1975</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc19-1785</pub-id>
<pub-id pub-id-type="pmid">32669412</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="dom15920-cit-0098">
<string-name>
<surname>Weisman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bai</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Cardinez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kramer</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta&#x02010;analysis of outpatient randomised controlled trials</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>(<issue>7</issue>):<fpage>501</fpage>&#x02010;<lpage>512</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(17)30167-5</pub-id>
<pub-id pub-id-type="pmid">28533136</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="dom15920-cit-0099">
<string-name>
<surname>Eckstein</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Weilguni</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tauschmann</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Time in range for closed&#x02010;loop systems versus standard of care during physical exercise in people with type 1 diabetes: a systematic review and meta&#x02010;analysis</article-title>. <source>J Clin Med</source>. <year>2021</year>;<volume>10</volume>(<issue>11</issue>):<elocation-id>2445</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/jcm10112445</pub-id>
<pub-id pub-id-type="pmid">34072900</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="dom15920-cit-0100">
<string-name>
<surname>Jiao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Better TIR, HbA1c, and less hypoglycemia in closed&#x02010;loop insulin system in patients with type 1 diabetes: a meta&#x02010;analysis</article-title>. <source>BMJ Open Diabetes Res Care</source>. <year>2022</year>;<volume>10</volume>(<issue>2</issue>):<elocation-id>e002633</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002633</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="dom15920-cit-0101">
<string-name>
<surname>Fang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>. <article-title>Efficacy and safety of closed&#x02010;loop insulin delivery versus sensor&#x02010;augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta&#x02010;analysis of randomized&#x02010;controlled trials</article-title>. <source>J Endocrinol Invest</source>. <year>2022</year>;<volume>45</volume>(<issue>3</issue>):<fpage>471</fpage>&#x02010;<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40618-021-01674-6</pub-id>
<pub-id pub-id-type="pmid">34535888</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="dom15920-cit-0102">
<string-name>
<surname>Zeng</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>F</given-names>
</string-name>. <article-title>Dual&#x02010;hormone artificial pancreas for glucose control in type 1 diabetes: a meta&#x02010;analysis</article-title>. <source>Diabetes Obes Metab</source>. <year>2022</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1967</fpage>&#x02010;<lpage>1975</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dom.14781</pub-id>
<pub-id pub-id-type="pmid">35638377</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="dom15920-cit-0103">
<string-name>
<surname>Beck</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Kanapka</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Breton</surname>
<given-names>MD</given-names>
</string-name>, et al. <article-title>A meta&#x02010;analysis of randomized trial outcomes for the t:slim X2 insulin pump with control&#x02010;IQ technology in youth and adults from age 2 to 72</article-title>. <source>Diabetes Technol Ther</source>. <year>2023</year>;<volume>25</volume>(<issue>5</issue>):<fpage>329</fpage>&#x02010;<lpage>342</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2022.0558</pub-id>
<pub-id pub-id-type="pmid">37067353</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="dom15920-cit-0104">
<string-name>
<surname>Ekhlaspour</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Town</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Raghinaru</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lum</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Buckingham</surname>
<given-names>BA</given-names>
</string-name>. <article-title>Glycemic outcomes in baseline hemoglobin A1C subgroups in the international diabetes closed&#x02010;loop trial</article-title>. <source>Diabetes Technol Ther</source>. <year>2022</year>;<volume>24</volume>(<issue>8</issue>):<fpage>588</fpage>&#x02010;<lpage>591</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2021.0524</pub-id>
<pub-id pub-id-type="pmid">35020488</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="dom15920-cit-0105">
<string-name>
<surname>Crabtree</surname>
<given-names>TSJ</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Yap</surname>
<given-names>YW</given-names>
</string-name>, et al. <article-title>Hybrid closed&#x02010;loop therapy in adults with type 1 diabetes and above&#x02010;target HbA1c: a real&#x02010;world observational study</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>10</issue>):<fpage>1831</fpage>&#x02010;<lpage>1838</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc23-0635</pub-id>
<pub-id pub-id-type="pmid">37566697</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="dom15920-cit-0106">
<string-name>
<surname>Benhalima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Beunen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Van Wilder</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel&#x02010;group, open&#x02010;label, randomised controlled trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2024</year>;<volume>12</volume>(<issue>6</issue>):<fpage>390</fpage>&#x02010;<lpage>403</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(24)00089-5</pub-id>
<pub-id pub-id-type="pmid">38697182</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="dom15920-cit-0107">
<string-name>
<surname>Lee</surname>
<given-names>TTM</given-names>
</string-name>, <string-name>
<surname>Collett</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bergford</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Automated insulin delivery in women with pregnancy complicated by type 1 diabetes</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>17</issue>):<fpage>1566</fpage>&#x02010;<lpage>1578</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2303911</pub-id>
<pub-id pub-id-type="pmid">37796241</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="dom15920-cit-0108">
<string-name>
<surname>Knoll</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Peacock</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>W&#x000e4;ldchen</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Real&#x02010;world evidence on clinical outcomes of people with type 1 diabetes using open&#x02010;source and commercial automated insulin dosing systems: a systematic review</article-title>. <source>Diabet Med</source>. <year>2022</year>;<volume>39</volume>(<issue>5</issue>):<elocation-id>e14741</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/dme.14741</pub-id>
<pub-id pub-id-type="pmid">34773301</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="dom15920-cit-0109">
<string-name>
<surname>Hussain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lal</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Braune</surname>
<given-names>K</given-names>
</string-name>. <article-title>Open&#x02010;source automated insulin delivery in type 1 diabetes&#x02014;the evidence is out there</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2022</year>;<volume>10</volume>(<issue>12</issue>):<fpage>835</fpage>&#x02010;<lpage>836</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(22)00283-2</pub-id>
<pub-id pub-id-type="pmid">36244346</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="dom15920-cit-0110">
<string-name>
<surname>Burnside</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Crocket</surname>
<given-names>HR</given-names>
</string-name>, et al. <article-title>Open&#x02010;source automated insulin delivery in type 1 diabetes</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>10</issue>):<fpage>869</fpage>&#x02010;<lpage>881</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2203913</pub-id>
<pub-id pub-id-type="pmid">36069869</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="dom15920-cit-0111">
<string-name>
<surname>Godoi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reis Marques</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Padr&#x000e3;o</surname>
<given-names>EMH</given-names>
</string-name>, et al. <article-title>Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96&#x02009;weeks in type 1 diabetes: a meta&#x02010;analysis of randomised controlled trials</article-title>. <source>Diabetol Metab Syndr</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>190</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13098-023-01144-4</pub-id>
<pub-id pub-id-type="pmid">37759290</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="dom15920-cit-0112">
<string-name>
<surname>Nefs</surname>
<given-names>G</given-names>
</string-name>. <article-title>The psychological implications of automated insulin delivery systems in type 1 diabetes care</article-title>. <source>Front Clin Diabetes Healthc</source>. <year>2022</year>;<volume>3</volume>:<elocation-id>846162</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fcdhc.2022.846162</pub-id>
<pub-id pub-id-type="pmid">36992780</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="dom15920-cit-0113">
<string-name>
<surname>Cobry</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Bisio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wadwa</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Breton</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed&#x02010;loop system</article-title>. <source>Diabetes Care</source>. <year>2022</year>;<volume>45</volume>(<issue>5</issue>):<fpage>1292</fpage>&#x02010;<lpage>1295</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc21-1778</pub-id>
<pub-id pub-id-type="pmid">35202468</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="dom15920-cit-0114">
<string-name>
<surname>Lawton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kimbell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Closs</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Listening to women: experiences of using closed&#x02010;loop in type 1 diabetes pregnancy</article-title>. <source>Diabetes Technol Ther</source>. <year>2023</year>;<volume>25</volume>(<issue>12</issue>):<fpage>845</fpage>&#x02010;<lpage>855</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2023.0323</pub-id>
<pub-id pub-id-type="pmid">37795883</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="dom15920-cit-0115">
<string-name>
<surname>Rankin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kimbell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Adolescents' experiences of using a smartphone application hosting a closed&#x02010;loop algorithm to manage type 1 diabetes in everyday life: qualitative study</article-title>. <source>J Diabetes Sci Technol</source>. <year>2021</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1042</fpage>&#x02010;<lpage>1051</lpage>. <ext-link xlink:href="https://www.oasis-open.org/2024/03/21/building-trust-in-ai-with-open-standards/" ext-link-type="uri">https://www.oasis-open.org/2024/03/21/building-trust-in-ai-with-open-standards/</ext-link>
<pub-id pub-id-type="pmid">34261348</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="dom15920-cit-0116">
<string-name>
<surname>Lawton</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Blackburn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rankin</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Participants' experiences of, and views about, daytime use of a day&#x02010;and&#x02010;night hybrid closed&#x02010;loop system in real life settings: longitudinal qualitative study</article-title>. <source>Diabetes Technol Ther</source>. <year>2019</year>;<volume>21</volume>(<issue>3</issue>):<fpage>119</fpage>&#x02010;<lpage>127</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2018.0306</pub-id>
<pub-id pub-id-type="pmid">30720338</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="dom15920-cit-0117">
<string-name>
<surname>Wang</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Malcolm</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Arnaout</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Humphrey&#x02010;Murto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>LaDonna</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Real&#x02010;world patient experience of long&#x02010;term hybrid closed&#x02010;loop insulin pump use</article-title>. <source>Can J Diabetes</source>. <year>2021</year>;<volume>45</volume>(<issue>8</issue>):<fpage>750</fpage>&#x02010;<lpage>756.e3</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcjd.2021.02.006</pub-id>
<pub-id pub-id-type="pmid">33958309</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="dom15920-cit-0118">
<string-name>
<surname>Davis</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>BW</given-names>
</string-name>, et al. <article-title>Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed&#x02010;loop therapy</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>4</issue>):<fpage>742</fpage>&#x02010;<lpage>750</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc22-1915</pub-id>
<pub-id pub-id-type="pmid">36787903</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="dom15920-cit-0119">
<string-name>
<surname>Levy</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Raghinaru</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kudva</surname>
<given-names>YC</given-names>
</string-name>, et al. <article-title>Beneficial effects of control&#x02010;IQ automated insulin delivery in basal&#x02010;bolus and basal&#x02010;only insulin users with type 2 diabetes</article-title>. <source>Clinical Diabetes</source>. <year>2024</year>;<volume>42</volume>(<issue>1</issue>):<fpage>116</fpage>&#x02010;<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.2337/cd23-0025</pub-id>
<pub-id pub-id-type="pmid">38230336</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="dom15920-cit-0120">
<string-name>
<surname>Scully</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Palani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Moheet</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Putman</surname>
<given-names>MS</given-names>
</string-name>. <article-title>The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis&#x02010;related diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2022</year>;<volume>24</volume>(<issue>6</issue>):<fpage>446</fpage>&#x02010;<lpage>452</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dia.2021.0354</pub-id>
<pub-id pub-id-type="pmid">35020476</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="dom15920-cit-0121">
<string-name>
<surname>Sherwood</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Jafri</surname>
<given-names>RZ</given-names>
</string-name>, <string-name>
<surname>Balliro</surname>
<given-names>CA</given-names>
</string-name>, et al. <article-title>Automated glycemic control with the bionic pancreas in cystic fibrosis&#x02010;related diabetes: a pilot study</article-title>. <source>J Cyst Fibros</source>. <year>2020</year>;<volume>19</volume>(<issue>1</issue>):<fpage>159</fpage>&#x02010;<lpage>161</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2019.08.002</pub-id>
<pub-id pub-id-type="pmid">31420176</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0122"><label>122</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0122">
<collab collab-type="authors">National Institute for Health and Care Research</collab>
. <article-title>Closed&#x02010;loop for people living with cystic fibrosis related diabetes (CL4P&#x02010;CF)</article-title>. Accessed June 24, 2024. <ext-link xlink:href="https://fundingawards.nihr.ac.uk/award/NIHR132299" ext-link-type="uri">https://fundingawards.nihr.ac.uk/award/NIHR132299</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="dom15920-cit-0123">
<string-name>
<surname>Thabit</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hartnell</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Closed&#x02010;loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel&#x02010;group trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>(<issue>2</issue>):<fpage>117</fpage>&#x02010;<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(16)30280-7</pub-id>
<pub-id pub-id-type="pmid">27836235</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="dom15920-cit-0124">
<string-name>
<surname>Bally</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Thabit</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hartnell</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Closed&#x02010;loop insulin delivery for glycemic control in noncritical care</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>6</issue>):<fpage>547</fpage>&#x02010;<lpage>556</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1805233</pub-id>
<pub-id pub-id-type="pmid">29940126</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0125"><label>125</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0125">
<article-title>National Institute for health and care excellent. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes technology appraisal guidance reference number:TA943</article-title>. <year>2023</year> Accessed February 21, 2024. <ext-link xlink:href="https://www.nice.org.uk/guidance/ta943/chapter/1-Recommendations" ext-link-type="uri">https://www.nice.org.uk/guidance/ta943/chapter/1-Recommendations</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="dom15920-cit-0126">
<article-title>7. Diabetes technology: standards of medical care in diabetes&#x02014;2021</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>(<issue>Supplement_1</issue>):<fpage>S85</fpage>&#x02010;<lpage>S99</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc21-S007</pub-id>
<pub-id pub-id-type="pmid">33298418</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0127"><label>127</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0127">
<collab collab-type="authors">NHS Digital</collab>
. <article-title>National Diabetes Insulin Pump Audit, 2017&#x02010;18</article-title>. <year>2019</year> Accessed February 23, 2024. <ext-link xlink:href="https://files.digital.nhs.uk/E0/030704/National%20Diabetes%20Insulin%20Pump%20Audit%202017-18%20Report%20v2.pdf" ext-link-type="uri">https://files.digital.nhs.uk/E0/030704/National%20Diabetes%20Insulin%20Pump%20Audit%202017&#x02010;18%20Report%20v2.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0128"><label>128</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0128">
<article-title>National Diabetes Audit, 2019&#x02010;20 Type 1 Diabetes. <italic toggle="yes">NHS Digital</italic>
</article-title>. <year>2019</year> Accessed February 23, 2024. <ext-link xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2019-20-type-1-diabetes" ext-link-type="uri">https://digital.nhs.uk/data&#x02010;and&#x02010;information/publications/statistical/national&#x02010;diabetes&#x02010;audit/national&#x02010;diabetes&#x02010;audit&#x02010;2019&#x02010;20&#x02010;type&#x02010;1&#x02010;diabetes</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="dom15920-cit-0129">
<string-name>
<surname>Lindner</surname>
<given-names>LME</given-names>
</string-name>, <string-name>
<surname>Rathmann</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Rosenbauer</surname>
<given-names>J</given-names>
</string-name>. <article-title>Inequalities in glycaemic control, hypoglycaemia and diabetic ketoacidosis according to socio&#x02010;economic status and area&#x02010;level deprivation in type 1 diabetes mellitus: a systematic review</article-title>. <source>Diabet Med</source>. <year>2018</year>;<volume>35</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02010;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dme.13519</pub-id>
<pub-id pub-id-type="pmid">28945942</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="dom15920-cit-0130">
<string-name>
<surname>Scott</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chambers</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goyder</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>O'Cathain</surname>
<given-names>A</given-names>
</string-name>. <article-title>Socioeconomic inequalities in mortality, morbidity and diabetes management for adults with type 1 diabetes: a systematic review</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>5</issue>):<elocation-id>e0177210</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0177210</pub-id>
<pub-id pub-id-type="pmid">28489876</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="dom15920-cit-0131">
<string-name>
<surname>Campbell</surname>
<given-names>RAS</given-names>
</string-name>, <string-name>
<surname>Colhoun</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Kennon</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Socio&#x02010;economic status and mortality in people with type 1 diabetes in Scotland 2006&#x02013;2015: a retrospective cohort study</article-title>. <source>Diabet Med</source>. <year>2020</year>;<volume>37</volume>(<issue>12</issue>):<fpage>2081</fpage>&#x02010;<lpage>2088</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dme.14239</pub-id>
<pub-id pub-id-type="pmid">31967666</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="dom15920-cit-0132">
<string-name>
<surname>Paisley</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Beynon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fullwood</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Impact of social deprivation, demographics and centre on HbA1c outcomes with continuous subcutaneous insulin infusion</article-title>. <source>Diabet Med</source>. <year>2019</year>;<volume>36</volume>(<issue>3</issue>):<fpage>383</fpage>&#x02010;<lpage>387</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dme.13833</pub-id>
<pub-id pub-id-type="pmid">30307056</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="dom15920-cit-0133">
<string-name>
<surname>Fallon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Oliver</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Avari</surname>
<given-names>P</given-names>
</string-name>. <article-title>The impact of socio&#x02010;economic deprivation on access to diabetes technology in adults with type 1 diabetes</article-title>. <source>Diabet Med</source>. <year>2022</year>;<volume>39</volume>(<issue>10</issue>):<elocation-id>e14906</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/dme.14906</pub-id>
<pub-id pub-id-type="pmid">35751860</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0134"><label>134</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0134">
<collab collab-type="authors">Juvenile Diabetes Research Foundation (JDRF)</collab>
. <article-title>JDRF pathway to choice report: a joint partnership Programme building awareness of and access to type 1 diabetes technology choices</article-title>. <year>2020</year> Accessed February 23, 2024. <ext-link xlink:href="https://jdrf.org.uk/wp-content/uploads/2023/06/JDRF-Pathway-to-Choice-report.pdf" ext-link-type="uri">https://jdrf.org.uk/wp-content/uploads/2023/06/JDRF-Pathway-to-Choice-report.pdf</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0135"><label>135</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0135">
<collab collab-type="authors">NHS England</collab>
. <article-title>Hybrid closed loop technologies: 5&#x02010;year implementation strategy</article-title>. <year>2024</year> Accessed February 21, 2024. <ext-link xlink:href="https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/" ext-link-type="uri">https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="dom15920-cit-0136">
<string-name>
<surname>Boughton</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Hartnell</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lakshman</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Fully closed&#x02010;loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single&#x02010;center, randomized, crossover study</article-title>. <source>Diabetes Care</source>. <year>2023</year>;<volume>46</volume>(<issue>11</issue>):<fpage>1916</fpage>&#x02010;<lpage>1922</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc23-0728</pub-id>
<pub-id pub-id-type="pmid">37616583</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="dom15920-cit-0137">
<string-name>
<surname>Jancev</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Snoek</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Frederix</surname>
<given-names>GWJ</given-names>
</string-name>, et al. <article-title>Dual hormone fully closed loop in type 1 diabetes: a randomised trial in the Netherlands &#x02013; study protocol</article-title>. <source>BMJ Open</source>. <year>2023</year>;<volume>13</volume>(<issue>8</issue>):<elocation-id>e074984</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2023-074984</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="dom15920-cit-0138">
<string-name>
<surname>Wolkowicz</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Aiello</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Vargas</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>A review of biomarkers in the context of type 1 diabetes: biological sensing for enhanced glucose control</article-title>. <source>Bioeng Transl Med</source>. <year>2021</year>;<volume>6</volume>(<issue>2</issue>):<elocation-id>e10201</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/btm2.10201</pub-id>
<pub-id pub-id-type="pmid">34027090</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="dom15920-cit-0139">
<string-name>
<surname>DeBoer</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Cher&#x000f1;avvsky</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Topchyan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kovatchev</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Francis</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Breton</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D</article-title>. <source>Pediatr Diabetes</source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>540</fpage>&#x02010;<lpage>546</lpage>. doi:<pub-id pub-id-type="doi">10.1111/pedi.12454</pub-id>
<pub-id pub-id-type="pmid">27734563</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="dom15920-cit-0140">
<string-name>
<surname>Corbett</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SA</given-names>
</string-name>, et al. <article-title>Smartwatch gesture&#x02010;based meal reminders improve glycaemic control</article-title>. <source>Diabetes Obes Metab</source>. <year>2022</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1667</fpage>&#x02010;<lpage>1670</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dom.14737</pub-id>
<pub-id pub-id-type="pmid">35491517</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0141"><label>141</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0141">
<collab collab-type="authors">Google Cloud</collab>
. <article-title>Artificial intelligence (AI) vs machine learning</article-title>. Accessed June 24, 2024. <ext-link xlink:href="https://cloud.google.com/learn/artificial-intelligence-vs-machine-learning" ext-link-type="uri">https://cloud.google.com/learn/artificial-intelligence-vs-machine-learning</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0142"><label>142</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0142">
<collab collab-type="authors">Bluetooth SIG</collab>
. <article-title>Auracast: a bluetooth technology</article-title>. Accessed July 2, 2024. <ext-link xlink:href="https://www.bluetooth.com/auracast/" ext-link-type="uri">https://www.bluetooth.com/auracast/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="dom15920-cit-0143">
<string-name>
<surname>Doctorow</surname>
<given-names>C</given-names>
</string-name>. <article-title>Competitive compatibility: let's fix the internet, not the tech giants</article-title>. <source>Commun ACM</source>. <year>2021</year>;<volume>64</volume>(<issue>10</issue>):<fpage>26</fpage>&#x02010;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1145/3446789</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0144"><label>144</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0144">
<collab collab-type="authors">Juvenile Diabetes Research Foundation</collab>
. <article-title>JDRF's UK position statement on type 1 diabetes &#x02018;DIY&#x02019; technologies</article-title>. <year>2024</year>
<ext-link xlink:href="https://jdrf.org.uk/about-jdrf-and-our-impact/about-jdrf/position-statements/jdrfs-uk-position-statement-on-type-1-diabetes-diy-technologies/" ext-link-type="uri">https://jdrf.org.uk/about-jdrf-and-our-impact/about-jdrf/position-statements/jdrfs-uk-position-statement-on-type-1-diabetes-diy-technologies/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0145"><label>145</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0145">
<string-name>
<surname>Lee</surname>
<given-names>M</given-names>
</string-name>. <article-title>Tidepool; interoperability is the how, not the why</article-title>.</mixed-citation></ref><ref id="dom15920-bib-0146"><label>146</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0146">
<collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>Product classification: integrated continuous glucose monitoring system, factory calibrated</article-title>. <year>2024</year> Accessed July 3, 2024. <ext-link xlink:href="https://accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=QBJ" ext-link-type="uri">https://accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=QBJ</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0147"><label>147</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0147">
<collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices</article-title>. <year>2018</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review" ext-link-type="uri">https://www.fda.gov/news&#x02010;events/press&#x02010;announcements/fda&#x02010;authorizes&#x02010;first&#x02010;fully&#x02010;interoperable&#x02010;continuous&#x02010;glucose&#x02010;monitoring&#x02010;system&#x02010;streamlines&#x02010;review</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0148"><label>148</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0148">
<collab collab-type="authors">Senseonics</collab>
. <article-title>Eversense&#x000ae; CGM system receives iCGM designation by the US FDA</article-title>. <year>2024</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.senseonics.com/investor-relations/news-releases/2024/04-30-2024-120116563" ext-link-type="uri">https://www.senseonics.com/investor-relations/news-releases/2024/04-30-2024-120116563</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0149"><label>149</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0149">
<collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>Product classification: alternate controller enabled insulin infusion pump</article-title>. <year>2024</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=QFG#:~:text=Alternate%20controller%20enabled%20infusion%20pump.&#x00026;text=An%20alternate%20controller%20enabled%20insulin,at%20set%20or%20variable%20rates" ext-link-type="uri">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=QFG#:~:text=Alternate%20controller%20enabled%20infusion%20pump.&#x00026;text=An%20alternate%20controller%20enabled%20insulin,at%20set%20or%20variable%20rates</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0150"><label>150</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0150">
<collab collab-type="authors">US Food and Drug Administation</collab>
. <article-title>Product classification: interoperable automated glycemic controller. Interoperable automated glycemic controller</article-title>. <year>2024</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=706#:~:text=Interoperable%20automated%20glycemic%20controllers%20are,received%2C%20executed%2C%20and%20confirmed" ext-link-type="uri">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=706#:~:text=Interoperable%20automated%20glycemic%20controllers%20are,received%2C%20executed%2C%20and%20confirmed</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0151"><label>151</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0151">
<collab collab-type="authors">Howard Look</collab>
. <article-title>Tidepool: Tidepool loop origin story</article-title>. <year>2023</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.tidepool.org/blog/tidepool-loop-origin-story" ext-link-type="uri">https://www.tidepool.org/blog/tidepool-loop-origin-story</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0152"><label>152</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0152">
<collab collab-type="authors">Howard Look</collab>
. <article-title>Tidepool loop has received FDA clearance!</article-title>
<year>2023</year> Accessed July 3, 2024. <ext-link xlink:href="https://www.tidepool.org/blog/tidepool-loop-has-received-fda-clearance" ext-link-type="uri">https://www.tidepool.org/blog/tidepool-loop-has-received-fda-clearance</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="dom15920-cit-0153">
<string-name>
<surname>Braune</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lal</surname>
<given-names>R</given-names>
</string-name>. <article-title>The first regulatory clearance of an open&#x02010;source automated insulin delivery algorithm</article-title>. <source>J Diabetes Sci Technol</source>. <year>2023</year>;<volume>17</volume>(<issue>5</issue>):<fpage>1139</fpage>&#x02010;<lpage>1141</lpage>. doi:<pub-id pub-id-type="doi">10.1177/19322968231164166</pub-id>
<pub-id pub-id-type="pmid">37051947</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0154"><label>154</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0154">
<collab collab-type="authors">GOV.UK</collab>
. <article-title>Policy paper open standards principles</article-title>. <year>2024</year>
<ext-link xlink:href="https://www.gov.uk/government/publications/open-standards-principles/open-standards-principles#:~:text=Principles%20for%20selecting%20open%20standards,-The%20government%20adopts&#x00026;text=Open%20standards%20must%20meet%20user%20needs.,standards%20must%20support%20sustainable%20cost" ext-link-type="uri">https://www.gov.uk/government/publications/open&#x02010;standards&#x02010;principles/open&#x02010;standards&#x02010;principles#:~:text=Principles%20for%20selecting%20open%20standards,&#x02010;The%20government%20adopts&#x00026;text=Open%20standards%20must%20meet%20user%20needs.,standards%20must%20support%20sustainable%20cost</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0155"><label>155</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0155">
<collab collab-type="authors">Francis Beland EDOO</collab>
. <article-title>Building trust in AI with open standards</article-title>. Accessed June 23, 2024. <ext-link xlink:href="https://www.oasis-open.org/2024/03/21/building-trust-in-ai-with-open-standards/" ext-link-type="uri">https://www.oasis-open.org/2024/03/21/building-trust-in-ai-with-open-standards/</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0156"><label>156</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0156">
<article-title>Standing Together: The Recommendations</article-title>. Accessed June 23, 2024. <ext-link xlink:href="https://www.datadiversity.org/recommendations" ext-link-type="uri">https://www.datadiversity.org/recommendations</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0157"><label>157</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0157">
<collab collab-type="authors">University of Birmingham</collab>
. <article-title>New standards released to ensure medical AI is safe and effective for everyone</article-title>. Accessed June 23, 2024. <ext-link xlink:href="https://www.birmingham.ac.uk/news/2023/new-standards-released-to-ensure-medical-ai-is-safe-and-effective-for-everyone" ext-link-type="uri">https://www.birmingham.ac.uk/news/2023/new&#x02010;standards&#x02010;released&#x02010;to&#x02010;ensure&#x02010;medical&#x02010;ai&#x02010;is&#x02010;safe&#x02010;and&#x02010;effective&#x02010;for&#x02010;everyone</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="dom15920-cit-0158">
<string-name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Simmonds</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>AK</given-names>
</string-name>. <article-title>The use of diabetes technology to address inequity in health outcomes: limitations and opportunities</article-title>. <source>Curr Diab Rep</source>. <year>2022</year>;<volume>22</volume>(<issue>7</issue>):<fpage>275</fpage>&#x02010;<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11892-022-01470-3</pub-id>
<pub-id pub-id-type="pmid">35648277</pub-id>
</mixed-citation></ref><ref id="dom15920-bib-0159"><label>159</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0159">
<collab collab-type="authors">NHS Digital</collab>
. <article-title>National Diabetes Audit &#x02010; insulin pump report 2017&#x02010;18</article-title>. <year>2019</year> Accessed July 3, 2024. <ext-link xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit---insulin-pump-report-2017-18" ext-link-type="uri">https://digital.nhs.uk/data&#x02010;and&#x02010;information/publications/statistical/national&#x02010;diabetes&#x02010;audit/national&#x02010;diabetes&#x02010;audit&#x02010;&#x02010;&#x02010;insulin&#x02010;pump&#x02010;report&#x02010;2017&#x02010;18</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0160"><label>160</label><mixed-citation publication-type="miscellaneous" id="dom15920-cit-0160">
<collab collab-type="authors">NHS Digital</collab>
. <article-title>National diabetes audit, 2019&#x02010;20, type 1 diabetes</article-title>. <year>2021</year> Accessed July 3, 2024. <ext-link xlink:href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2019-20-type-1-diabetes" ext-link-type="uri">https://digital.nhs.uk/data&#x02010;and&#x02010;information/publications/statistical/national&#x02010;diabetes&#x02010;audit/national&#x02010;diabetes&#x02010;audit&#x02010;2019&#x02010;20&#x02010;type&#x02010;1&#x02010;diabetes</ext-link>
</mixed-citation></ref><ref id="dom15920-bib-0161"><label>161</label><mixed-citation publication-type="journal" id="dom15920-cit-0161">
<string-name>
<surname>Akturk</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hoffecker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>VN</given-names>
</string-name>. <article-title>Inequity in racial&#x02010;ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>(<issue>6</issue>):<fpage>e121</fpage>&#x02010;<lpage>e123</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc20-3063</pub-id>
<pub-id pub-id-type="pmid">34016613</pub-id>
</mixed-citation></ref></ref-list></back></article>